UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

	FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2008

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

	FOR THE TRANSITION PERIOD FROM TO .

Commission File No. 001-31298

LANNETT COMPANY, INC.

(Exact Name of Registrant as Specified in its Charter)

State of Delaware		23-0787699
(State of Incorporation)		(I.R.S. Employer I.D. No.)

9000 State Road
Philadelphia, PA 19136
(215) 333-9000
(Address of principal executive offices and telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes x

No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o		Accelerated filer o

Non-accelerated filer o		Smaller reporting company x
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12B-12 of the Exchange Act).

Yes o

No x

As of May 13, 2008, there were 24,283,963 shares of the issuer’s common stock, $.001 par value, outstanding.

Table of Contents

			Page No.

PART I. FINANCIAL INFORMATION

ITEM 1.		FINANCIAL STATEMENTS

		Consolidated Balance Sheets as of March 31, 2008 (unaudited) and June 30, 2007	1

		Consolidated Statements of Operations (unaudited) for the three months and nine months ended March 31, 2008 and 2007	2

		Consolidated Statement of Changes in Shareholders’ Equity (unaudited for the nine months ended March 31, 2008)	3

		Consolidated Statements of Cash Flows (unaudited) for the nine months ended March 31, 2008 and 2007	4

		Notes to Consolidated Financial Statements (unaudited)	5

ITEM 2.		MANAGEMENT’S DISCUSSION AND ANALYSIS OFFINANCIAL CONDITION AND RESULTS OF OPERATIONS	30

ITEM 3.		QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	43

ITEM 4.	CONTROLS AND PROCEDURES		43

PART II. OTHER INFORMATION

ITEM 1.	LEGAL PROCEEDINGS		44

ITEM 4.	SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS		44

ITEM 6.	EXHIBITS AND REPORTS ON FORM 8-K		45

CERTIFICATION OF PRESIDENT & CHIEF EXECUTIVE OFFICER

CERTIFICATION OF VICE PRESIDENT OF FINANCE, TREASURER & CHIEF FINANCIAL OFFICER

CERTIFICATION PURSUANT TO SECTION 906 OF SARBANES OXLEY ACT OF 2002

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

LANNETT COMPANY, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

	March 31, 2008			June 30, 2007
	(unaudited)
ASSETS
Current Assets
Cash	$	6,599,019		$	5,192,341
Trade accounts receivable (net of allowance of $438,000 and $250,000, respectively)	18,946,727			19,473,978
Inventories	12,018,415			14,518,484
Interest receivable	69,483			36,260
Prepaid taxes	3,193,685			3,193,685
Deferred tax assets - current portion	1,590,175			1,258,930
Other current assets	536,368			611,512
Total Current Assets	42,953,872			44,285,190

Property, plant, and equipment	39,310,358			39,260,689
Less accumulated depreciation	(14,224,639		)	(11,817,528		)
	25,085,719			27,443,161

Construction in progress	923,545			176,003
Investment securities - available for sale	2,502,755			3,320,632
Intangible asset (product rights) - net of accumulated amortization	10,808,001			12,046,502
Deferred tax assets	18,877,745			17,150,174
Other assets	204,382			234,438
TOTAL ASSETS	$	101,356,019		$	104,656,100

LIABILITIES AND SHAREHOLDERS’ EQUITY
LIABILITIES
Current Liabilities
Accounts payable	$	8,787,457		$	7,013,985
Accrued expenses	2,965,743			6,719,782
Deferred revenue	1,177,189			1,637,993
Unearned grant funds	500,000			500,000
Current portion of long term debt	703,570			692,119
Rebates and chargebacks payable	6,148,307			5,686,364
Total Current Liabilities	20,282,266			22,250,243

Long term debt, less current portion	8,533,181			8,987,846
Deferred tax liabilities	3,226,090			3,202,835
Other long term liabilities	30,080			32,001
TOTAL LIABILITIES	32,071,617			34,472,925

SHAREHOLDERS’ EQUITY
Common stock - authorized 50,000,000 shares, par value $0.001; issued and outstanding - 24,270,577 and 24,171,217 shares, respectively	24,271			24,171

Additional paid-in capital	74,208,805			73,053,778
Accumulated deficit	(4,513,174		)	(2,472,621		)
Accumulated other comprehensive income (loss)	33,446			(27,583		)
	69,753,348			70,577,745
Less: Treasury stock at cost - 74,970 shares and 50,900 shares, respectively	(468,946		)	(394,570		)
TOTAL SHAREHOLDERS’ EQUITY	69,284,402			70,183,175
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	101,356,019		$	104,656,100

The accompanying notes to consolidated financial statements are an integral part of these statements.

LANNETT COMPANY, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

	Three months ended						Nine months ended
	March 31,						March 31,
	2008			2007			2008			2007

Net sales	$	16,579,512		$	20,302,576		$	51,654,484		$	65,186,747
Cost of sales	12,276,526			14,127,421			36,688,446			44,770,101
Amortization of intangible assets	446,166			446,166			1,338,498			1,338,498
Product Royalties	(40,674		)	516,576			196,672			1,746,200

Gross profit	3,897,494			5,212,413			13,430,868			17,331,948

Research and development expenses	1,516,904			2,269,677			3,715,334			5,586,213
Selling, general, and administrative expenses	4,222,103			2,615,910			12,457,030			7,739,524
Loss on impairment	—			7,775,890			—			7,775,890

Operating loss	(1,841,513		)	(7,449,064		)	(2,741,496		)	(3,769,679		)

OTHER INCOME(EXPENSE):
Interest income	45,239			99,000			170,967			309,805
Interest expense	(75,025		)	(76,102		)	(291,146		)	(208,497		)
	(29,786		)	22,898			(120,179		)	101,308

Loss before income tax (benefit) expense	(1,871,299		)	(7,426,166		)	(2,861,675		)	(3,668,371		)

Income tax (benefit) expense	(615,454		)	(818,807		)	(821,122		)	685,791

Net loss	$	(1,255,845	)	$	(6,607,359	)	$	(2,040,553	)	$	(4,354,162	)

Basic loss per common share	$	(0.05	)	$	(0.27	)	$	(0.08	)	$	(0.18	)
Diluted loss per common share	$	(0.05	)	$	(0.27	)	$	(0.08	)	$	(0.18	)

Basic weighted average number of shares	24,268,449			24,164,385			24,208,830			24,155,556
Diluted weighted average number of shares	24,268,449			24,164,385			24,208,830			24,155,556

The accompanying notes to consolidated financial statements are an integral part of these statements.

LANNETT COMPANY, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY

(UNAUDITED)

	Common Stock			Additional								Accum. Other
	Shares			Paid-in		Accumulated			Treasury			Comp. (Loss)			Shareholders’
	Issued	Amount		Capital		Deficit			Stock			Income			Equity

Balance, June 30, 2007	24,171,217	$	24,171	$	73,053,778	$	(2,472,621	)	$	(394,570	)	$	(27,583	)	$	70,183,175

Shares issued in connection with employee stock purchase plan	24,896	25		106,479		—			—			—			106,504
Share based compensation
Restricted stock	—	—		91,905		—			—			—			91,905
Stock options	—	—		656,628		—			—			—			656,628
Shares issued in connection with restricted stock grant	74,464	75		300,015		—			—			—			300,090
Purchase of treasury stock	—	—		—		—			(74,376		)	—			(74,376		)
Other comprehensive income, net of income tax	—	—		—		—			—			61,029			61,029
Net loss	—	—		—		(2,040,553		)	—			—			(2,040,553		)

Balance, March 31, 2008	24,270,577	$	24,271	$	74,208,805	$	(4,513,174	)	$	(468,946	)	$	33,446		$	69,284,402

The accompanying notes to consolidated financial statements are an integral part of these statements.

LANNETT COMPANY, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

	For the nine months ended March 31,
	2008			2007

OPERATING ACTIVITIES:
Net loss	$	(2,040,553	)	$	(4,354,162	)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	3,745,611			3,293,232
Deferred tax expense	(821,183		)	704,125
Stock compensation expense	768,922			856,868
Gain from sale of asset	—			(8,208		)
Restricted stock grant	300,090			—
Loss on impairment	—			7,775,890
Other noncash expenses	11,418			—
Changes in assets and liabilities which provided (used) cash:
Trade accounts receivable	989,194			(5,188,226		)
Inventories	2,500,069			(935,028		)
Prepaid taxes	—			366,488
Prepaid expenses and other assets	(41,362		)	(134,053		)
Accounts payable	1,773,472			8,639,319
Accrued expenses	(3,754,038		)	519,154
Deferred revenue	(460,804		)	—
Net cash provided by operating activities	2,970,836			11,535,399

INVESTING ACTIVITIES:
Purchases of property, plant and equipment (including construction in progress)	(2,052,276		)	(1,949,407		)
Proceeds from sale of asset	—			10,000
Proceeds from sale of investment securities - available for sale	1,520,198			1,876,617
Purchase of investment securities - available for sale	(600,605		)
Issuance of note receivable	—			(7,327,238		)
Net cash used in investing activities	(1,132,683		)	(7,390,028		)

FINANCING ACTIVITIES:
Repayments of debt	(443,214		)	(406,260		)
Proceeds from issuance of stock	86,115			109,379
Treasury stock transactions	(74,376		)	—
Net cash used in financing activities	(431,475		)	(296,881		)

NET INCREASE IN CASH	1,406,678			3,848,490

CASH, BEGINNING OF PERIOD	5,192,341			468,359

CASH, END OF PERIOD	$	6,599,019		$	4,316,849

SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION -
Interest paid	$	97,114		$	121,833
Income taxes paid	$	—		$	650,000

The accompanying notes to consolidated financial statements are an integral part of these statements.

LANNETT COMPANY, INC. AND SUBSIDIARIES

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED

Note 1. Interim Financial Information

The accompanying unaudited financial statements have been prepared in accordance with U.S. generally accepted accounting principles for presentation of interim financial statements and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited financial statements do not include all the information and footnotes necessary for a comprehensive presentation of the financial position, results of operations, and cash flows for the periods presented. In the opinion of management, the unaudited financial statements include all the normal recurring adjustments that are necessary for a fair presentation of the financial position, results of operations, and cash flows for the periods presented. Operating results for the three month and nine month periods ended March 31, 2008 are not necessarily indicative of the results that may be expected for the fiscal year ending June 30, 2008. You should read these unaudited financial statements in combination with the other Notes in this section; “Management’s Discussion and Analysis of Financial Condition and Results of Operations” appearing in Item 2; and the Financial Statements, including the Notes to the Financial Statements, included in our Annual Report on Form 10-K for the fiscal year ended June 30, 2007.

Note 2. Summary of Significant Accounting Policies

Lannett Company, Inc., a Delaware corporation, and subsidiaries (the “Company” or “Lannett”), develop, manufacture, package, market, and distribute active pharmaceutical ingredients as well as pharmaceutical products sold under generic chemical names. The Company primarily manufactures solid oral dosage forms, including tablets and capsules, and is pursuing partnerships and research contracts for the development and production of other dosage forms, including liquids and injectable products.

Use of Estimates –The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Principles of Consolidation - The consolidated financial statements include the accounts of the operating parent company, Lannett Company, Inc., and its wholly owned subsidiaries, Lannett Holdings, Inc. and Cody Laboratories, Inc. (“Cody”). Cody includes the consolidation of Cody LCI Realty, LLC, a variable interest entity, as a result of the acquisition of Cody, April 10, 2007. See Note 17 about the consolidation of this variable interest entity. All intercompany accounts and transactions have been eliminated.

Reclassifications - Certain reclassifications have been made to prior year amounts to conform to the current year presentation.

Revenue Recognition - The Company recognizes revenue when its products are shipped to the customer. At this point, title and risk of loss have transferred to the customer and provisions for estimates, including rebates, promotional adjustments, price adjustments, returns, chargebacks, and other potential adjustments are reasonably determinable. Accruals for these provisions are presented in the consolidated financial statements as rebates and chargebacks payable and reductions to net sales. The change in the reserves for various sales adjustments may not be proportionally equal to the change in sales because of changes in both the product and the customer mix. Increased sales to wholesalers will generally require additional accruals as they are the primary recipient of

chargebacks and rebates. Incentives offered to secure sales vary from product to product. Provisions for rebates and promotional credits are estimated based upon contractual terms. Provisions for other customer credits, such as price adjustments, returns, and chargebacks, require management to make subjective judgments on customer mix. Unlike branded innovator drug companies, Lannett does not use information about product levels in distribution channels from third-party sources, such as IMS and Wolters Kluwer, in estimating future returns and other credits. Lannett calculates a chargeback/rebate rate based on contractual terms with its customers and applies this rate to customer sales. The only variable is customer mix, and this assumption is based on historical data and sales expectations. The chargeback/rebate reserve is reviewed on a monthly basis by management using several ratios and calculated metrics. While the Company may continue to improve its processes related to estimating and verifying its liabilities related to these provisions, Lannett’s methodology for estimating reserves has been consistent with previous periods.

Chargebacks – The provision for chargebacks is the most significant and complex estimate used in the recognition of revenue. The Company sells its products directly to wholesale distributors, generic distributors, retail pharmacy chains, and mail-order pharmacies. The Company also sells its products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, and group purchasing organizations, collectively referred to as “indirect customers.” Lannett enters into agreements with its indirect customers to establish pricing for certain products. The indirect customers then independently select a wholesaler from which to actually purchase the products at these agreed-upon prices. Lannett will provide credit to the wholesaler for the difference between the agreed-upon price with the indirect customer and the wholesaler’s invoice price if the price sold to the indirect customer is lower than the direct price to the wholesaler. This credit is called a chargeback. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to the indirect customers and estimated wholesaler inventory levels. As sales to the large wholesale customers, such as Cardinal Health, AmerisourceBergen, and McKesson, increase, the reserve for chargebacks will also generally increase. However, the size of the increase depends on the product mix. The Company continually monitors the reserve for chargebacks and makes adjustments when management believes that expected chargebacks on actual sales may differ from actual chargeback reserves.

Rebates – Rebates are offered to the Company’s key chain drug store, distributor and wholesaler customers to promote customer loyalty and increase product sales. These rebate programs provide customers with rebate credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. At the time of shipment, the Company estimates reserves for rebates and other promotional credit programs based on the specific terms in each agreement. The reserve for rebates increases as sales to certain wholesale and retail customers increase. However, since these rebate programs are not identical for all customers, the size of the reserve will depend on the mix of customers that are eligible to receive rebates.

Returns – Consistent with industry practice, the Company has a product returns policy that allows customers to return product within a specified period prior to and subsequent to the product’s lot expiration date in exchange for a credit to be applied to future purchases. The Company’s policy requires that the customer obtain pre-approval from the Company for any qualifying return. The Company estimates its provision for returns based on historical experience, changes to business practices, and credit terms. While such experience has allowed for reasonable estimations in the past, history may not always be an accurate indicator of future returns. The Company continually monitors the provisions for returns and makes adjustments when management believes that actual product returns may differ from established reserves. Generally, the reserve for returns increases as net sales increase. The reserve for returns is included in the rebates and chargebacks payable account on the balance sheet.

estimated shelf stock adjustments are based upon specified terms with direct customers, estimated declines in market prices, and estimates of inventory held by customers. The Company regularly monitors these and other factors and evaluates the reserve as additional information becomes available. Other adjustments are included in the rebates and chargebacks payable account on the balance sheet.

The following tables identify the reserves for each major category of revenue allowance and a summary of the activity for the nine months ended March 31, 2008 and 2007:

For the nine months ended March 31, 2008

Reserve Category	Chargebacks			Rebates			Returns			Other			Total

Reserve Balance as of June 30, 2007	$	4,649,478		$	871,339		$	113,313		$	52,234		$	5,686,364
Actual credits issued related to sales recorded in prior fiscal years	(4,429,923		)	(1,741,804		)	(146,917		)	—			(6,318,644		)
Reserves or (reversals) charged during Fiscal 2008 related to sales in prior fiscal years	—			870,465			50,000			(50,000		)	870,465
Reserves charged to net sales during Fiscal 2008 related to sales recorded in Fiscal 2008	17,985,506			6,240,517			2,200,267			473,423			26,899,713
Actual credits issued related to sales recorded in Fiscal 2008	(14,721,493		)	(4,988,844		)	(805,702		)	(473,552		)	(20,989,591		)

Reserve Balance as of March 31, 2008	$	3,483,568		$	1,251,673		$	1,410,961		$	2,105		$	6,148,307

For the nine months ended March 31, 2007

Reserve Category	Chargebacks			Rebates			Returns			Other			Total

Reserve balance as of June 30, 2006	$	10,137,400		$	2,183,100		$	416,000		$	275,600		$	13,012,100
Actual credits issued related to sales recorded in prior fiscal years	(10,170,000		)	(1,800,000		)	(890,000		)	(250,000		)	(13,110,000		)
Reserves or (reversals) charged during Fiscal 2007 related to sales in prior fiscal years	—			(300,000		)	460,000			—			160,000
Reserves charged to net sales during Fiscal 2007 related to sales recorded in Fiscal 2007	24,340,700			8,832,300			986,400			1,033,100			35,192,500
Actual credits issued related to sales recorded in Fiscal 2007	(17,065,500		)	(5,122,200		)	(954,700		)	(265,000		)	(23,407,400		)
Reserve Balance as of March 31, 2007	$	7,242,600		$	3,793,200		$	17,700		$	793,700		$	11,847,200

The Company ships its products to the warehouses of its wholesale and retail chain customers. When the Company and a customer come to an agreement for the supply of a product, the customer will generally continue to purchase the product, stock its warehouse(s), and resell the product to its own customers. The Company’s customer will reorder the product as its warehouse is depleted. The Company generally has no minimum size orders for its customers. Additionally, most warehousing customers prefer not to stock excess inventory levels due to the additional carrying costs and inefficiencies created by holding excess inventory. As such, the Company’s customers continually reorder the Company’s products. It is common for the Company’s customers to order the same products on a monthly basis. For generic pharmaceutical manufacturers, it is critical to ensure that customers’ warehouses are adequately stocked with its products. This is important due to the fact that several generic competitors compete for the consumer demand for a given product. Availability of inventory ensures that a manufacturer’s product is considered. Otherwise, retail prescriptions would be filled with

competitors’ products. For this reason, the Company periodically offers incentives to its customers to purchase its products. These incentives are generally up-front discounts off its standard prices at the beginning of a generic campaign launch for a newly-approved or newly-introduced product, or when a customer purchases a Lannett product for the first time. Customers generally inform the Company that such purchases represent an estimate of expected resale for a period of time. This period of time is generally up to three months. The Company records this revenue, net of any discounts offered and accepted by its customers at the time of shipment. The Company’s products generally have either 24 months or 36 months of shelf-life at the time of manufacture. The Company monitors its customers’ purchasing trends to attempt to identify any significant lapses in purchasing activity. If the Company observes a lack of recent activity, inquiries will be made to such customer regarding the success of the customer’s resale efforts. The Company attempts to minimize any potential return (or shelf life issues) by maintaining an active dialogue with the customers.

The products that the Company sells are generic versions of brand named drugs. The consumer markets for such drugs are well-established markets with many years of historically-confirmed consumer demand. Such consumer demand may be affected by several factors, including alternative treatments and costs, etc. However, the effects of changes in such consumer demand for the Company’s products, like generic products manufactured by other generic companies, are gradual in nature. Any overall decrease in consumer demand for generic products generally occurs over an extended period of time. This is because there are thousands of doctors, prescribers, third-party payers, institutional formularies and other buyers of drugs that must change prescribing habits and medicinal practices before such a decrease would affect a generic drug market. If the historical data the Company uses and the assumptions management makes to calculate its estimates of future returns, chargebacks, and other credits do not accurately approximate future activity, its net sales, gross profit, net income and earnings per share could change. However, management believes that these estimates are reasonable based upon historical experience and current conditions.

Accounts Receivable - The Company performs ongoing credit evaluations of its customers and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by a review of current credit information. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within both the Company’s expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same credit loss rates that it has in the past.

Credit terms are offered to customers based on evaluations of the customers’ financial condition. Generally, collateral is not required from customers. Accounts receivable payment terms vary and are stated in the financial statements at amounts due from customers net of an allowance for doubtful accounts. Accounts remaining outstanding longer than the payment terms are considered past due. The Company determines its allowance by considering a number of factors, including the length of time trade accounts receivable are past due, the Company’s previous loss history, the customer’s current ability to pay its obligation to the Company, and the condition of the general economy and the industry as a whole. The Company writes-off accounts receivable when they become uncollectible, and payments subsequently received on such receivables are credited to the allowance for doubtful accounts.

Fair Value of Financial Instruments - The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued expenses and debt obligations. The carrying values of these assets and liabilities approximate fair value based upon the short-term nature of these instruments. The Company has estimated that the fair value of long-term debt associated with the 20 year mortgage on its land and building in Cody, Wyoming approximates the discounted amount of future payments to the mortgage-holder. There is no market for this type of financial liability. The Company estimates that the fair value of the mortgage liability is less than the carrying value of the property.

Investment Securities - The Company’s investment securities consist of marketable debt securities, primarily in U.S. government and agency obligations. All of the Company’s marketable debt securities are classified as available-for-sale and recorded at fair value, based on quoted market prices. Unrealized holding gains and losses are recorded, net of any tax effect, as a separate component of accumulated other comprehensive loss. No gains or losses on marketable debt securities are realized until they are sold or a decline in fair value is determined to be other-than-temporary. If a decline in fair value is determined to be other-than-temporary, an impairment charge is recorded and a new cost basis in the investment is established.

Shipping and Handling Costs – The cost of shipping products to customers is recognized at the time the products are shipped, and is included in Cost of Sales.

Research and Development – Research and development expenses are charged to operations as incurred.

Intangible Assets – On March 23, 2004, the Company entered into an agreement with Jerome Stevens Pharmaceuticals, Inc. (JSP) for the exclusive marketing and distribution rights in the United States to the current line of JSP products in exchange for four million (4,000,000) shares of the Company’s common stock. As a result of the JSP agreement, the Company recorded an intangible asset of $67,040,000 for the exclusive marketing and distribution rights obtained from JSP. The intangible asset was recorded based upon the fair value of the four million (4,000,000) shares at the time of issuance to JSP.

In June 2004, JSP’s Levothyroxine Sodium tablet product received from the FDA an AB rating to the brand drug Levoxyl^®. In December 2004, the product received from the FDA a second AB rating to the brand drug Synthroid^®. As a result of the dual AB ratings, the Company was required to pay JSP an additional $1.5 million in cash to reimburse JSP for expenses related to obtaining the AB ratings. As of June 30, 2005, the Company had recorded an addition to the intangible asset of $1.5 million.

During Fiscal 2005, events occurred (as described in subsequent paragraphs) which indicated that the carrying value of the intangible asset was not recoverable. In accordance with Statement of Financial Accounting Standards No. 144 (FAS 144), Accounting for the Impairment or Disposal of Long-Lived Assets, the Company engaged a third party valuation specialist to assist in the performance of an impairment test for the quarter ended March 31, 2005. The impairment test was performed by discounting forecasted future net cash flows for the JSP products covered under the agreement and then comparing the discounted present value of those cash flows to the carrying value of the asset (inclusive of the $1.5 million payable to JSP for the second AB rating). As a result of the testing, the Company had determined that the intangible asset was impaired as of March 31, 2005. In accordance with FAS 144, the Company recorded a non-cash impairment loss of approximately $46,093,000 to write the asset down to its fair value of approximately $16,062,000 as of the date of the impairment. This impairment loss was shown on the statement of operations as a component of operating loss. Management concluded that, as of March 31, 2008, the intangible asset was correctly stated at net realizable value of approximately $10,708,000 and, therefore, no adjustment was required.

Several factors contributed to the impairment of this asset. In December 2004, the Levothyroxine Sodium tablet product received the AB rating to Synthroid^®. The expected sales increase as a result of the AB rating did not occur in the third quarter of 2005. The delay in receiving the AB rating to Synthroid^® caused the Company to be competitively disadvantaged with its Levothyroxine Sodium tablet product and to lose market share to competitors whose products had already received AB ratings to both major brand thyroid deficiency drugs. Additionally, the generic market for thyroid deficiency drugs turned out to be smaller than it was anticipated to be as a result of a lower brand-to-generic substitution rate. Increased competition in the generic drug market, both from existing competitors and new entrants, has resulted in significant pricing pressure on other products supplied by JSP. The combination of these factors resulted in diminished forecasted future net cash flow which, when discounted, yield a lower present value than the carrying value of the asset before impairment.

The Company will incur annual amortization expense of approximately $1,785,000 for the intangible asset over the remaining term of the contract. For each nine month period ended March 31, 2008 and 2007, the Company incurred amortization expense of approximately $1,338,000.

Future annual amortization expense of the JSP intangible asset consists of approximately the following:

Fiscal Year Ending June 30,	Annual Amortization Expense
2008	$	446,000
2009	1,785,000
2010	1,785,000
2011	1,785,000
2012	1,785,000
Thereafter	3,122,000
	$	10,708,000

Advertising Costs - The Company charges advertising costs to operations as incurred. Advertising expense for the nine months ended March 31, 2008 and 2007 was approximately $5,000 and $49,000, respectively.

Income Taxes - The Company uses the liability method specified by Statement of Financial Accounting Standards No. 109 (FAS), Accounting for Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. Deferred tax expense/ (benefit) is the result of changes in deferred tax assets and liabilities.

Segment Information – The Company reports segment information in accordance with Statement of Financial Accounting Standard No. 131 (FAS 131), Disclosures about Segments of an Enterprise and Related Information. The Company operates one business segment - generic pharmaceuticals, accordingly the Company has one reporting segment. In accordance with FAS 131, the Company aggregates its financial information for all products and reports as one operating segment. The following table identifies the Company’s approximate net product sales by medical indication for the three and nine months ended March 31, 2008 and 2007:

	For the Three Months Ended March 31,				For the Nine Months Ended March 31,
Medical Indication	2008		2007		2008		2007

Migraine Headache	$	2,373,000	$	2,851,000	$	7,815,000	$	8,013,000
Epilepsy	816,000		2,071,000		2,787,000		6,544,000
Heart Failure	1,004,000		1,029,000		3,164,000		3,532,000
Thyroid Deficiency	9,288,000		8,338,000		27,974,000		26,617,000
Antibiotic	2,293,000		5,310,000		7,378,000		17,512,000
Other	806,000		704,000		2,536,000		2,969,000

Total	$	16,580,000	$	20,303,000	$	51,654,000	$	65,187,000

Concentration of Market and Credit Risk - Six of the Company’s products, defined as generics containing the same active ingredient or combination of ingredients, accounted for approximately 54%, 10%, 8%, 7%, 6% and 5% of net sales for the nine months ended March 31, 2008. Those same products accounted for 41%, 23%, 7%, 5%, 5% and 10%, respectively, of net sales for the nine months ended March 31, 2007. For the three months ended March 31, 2008 and 2007, the same six products accounted for 56%, 9%, 8%, 7%, 6% and 5%, and 41%, 23%, 10%, 9%, 6% and 5% of net sales, respectively.

Four of the Company’s customers accounted for 32%, 9%, 5%, and 5%, respectively, of net sales for the nine months ended March 31, 2008, and 16%, 8%, 20%, and 3%, respectively, of net sales for the nine months ended March 31, 2007. The same four customers accounted for 29%, 6%, 5%, and 4%, respectively, of net sales for the three months ended March 31, 2008 of this year, and 15%, 8%, 13%, and 3%, respectively, of net sales for the three months ended March 31, 2007. At March 31, 2008, these four customers accounted for 58% of the Company’s accounts receivable balances. At June 30, 2007, these four customers accounted for 53% of the Company’s accounts receivable balances.

Share-based Compensation - The Company follows the guidance in Financial Accounting Standards Board (FASB) Statement of Financial Accounting Standards (SFAS) No. 123 (R), “Share-Based Payment” (SFAS 123(R)). This standard is a revision of SFAS 123, “Accounting for Stock-Based Compensation” and supersedes Accounting Principles Board Opinion (“APB”) No. 25, “Accounting for Stock Issued to Employees.” SFAS 123(R) addresses the accounting for share-based compensation in which we receive employee services in exchange for our equity instruments. Under the standard, we recognize compensation cost for share-based compensation issued to or purchased by employees, net of estimated forfeitures, under share-based compensation plans using a fair value method.

At March 31, 2008, the Company had three stock-based employee compensation plans (the “Old Plan,” the “2003 Plan,” and the “Long-term Incentive Plan,” or “LTIP”). During the nine months ended March 31, 2008, the Company awarded 209,264 shares of restricted stock under the LTIP of which, 74,464 of these shares vested 100% on January 1, 2008, the remainder vest in equal portions on September 18, 2008, 2009 and 2010. Stock compensation expense of $42,889 and $91,905 was recognized during the three-months and nine months ended March 31, 2008, respectively, related to these shares of restricted stock.

The Company is required to record compensation expense for all awards granted after the date of adoption of SFAS 123(R) and for the unvested portion of previously granted awards that remain outstanding as of the beginning of the period of adoption. The Company measures share-based compensation cost for options using the Black-Scholes option pricing model. The following table presents the weighted average assumptions used to estimate fair values of the stock options granted and the estimated forfeiture rates during the nine months ended March 31:

	Incentive Stock Options			Non-qualified Stock Options			Incentive Stock Options			Non-qualified Stock Options
	FY 2008			FY 2008			FY 2007			FY 2007
Risk-free interest rate	4.2		%	4.2		%	4.7		%	4.8		%
Expected volatility	56.0		%	56.0		%	59.0		%	59.0		%
Expected dividend yield	0.0		%	0.0		%	0.0		%	0.0		%
Forfeiture rate	5.0		%	5.0		%	5.0		%	5.0		%
Expected term	5.0 years			5.0 years			5.0 years			5.0 years
Weighted average fair value at date of grant	$	2.11		$	2.11		$	3.36		$	3.20

Zero options and approximately 548,000 options were issued under the LTIP during the three and nine months ended March 31, 2008, respectively. Zero options and approximately 354,000 options were issued under the 2003 Plan during the three and nine months ended March 31, 2007, respectively. There were no shares under option that were exercised in the three and nine months ended March 31, 2008. Three hundred seventy-five shares under option were exercised in the three and nine months ended March 31, 2007, resulting in proceeds of $281 to the Company. At March 31, 2008, there were 1,660,431 options outstanding. Of those, 548,000 were options issued under the LTIP, 901,198 were issued under the 2003 Plan, and 211,233 under the Old Plan. There are no further shares authorized to be issued under the Old Plan. 1,125,000 shares were authorized to be issued under the 2003 Plan, with 7,690 shares under option having already been exercised under that plan. 2,500,000 shares were authorized to be issued under the LTIP, with no shares under options having yet been exercised under that plan.

Expected volatility is based on the historical volatility of the price of our common shares since the date we commenced trading on the American Stock Exchange in April 2002. We use historical information to estimate expected term within the valuation model. The expected term of awards represents the period of time that options granted are expected to be outstanding. The risk-free rate for periods within the expected life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. Compensation cost is recognized using a straight-line method over the vesting or service period and is net of estimated forfeitures.

The forfeiture rate assumption is the estimated annual rate at which unvested awards are expected to be forfeited during the vesting period. This assumption is based on our historical forfeiture rate. Periodically, management will assess whether it is necessary to adjust the estimated rate to reflect changes in actual forfeitures or changes in expectations. For example, adjustments may be needed if forfeitures were affected by turnover that resulted from a business restructuring that is not expected to recur. The forfeiture rate is 5% at March 31, 2008 and 2007. As the Company continues to grow, this rate is likely to change to match such changes in turnover and hiring rates. Under the provisions of FAS 123R, the Company will incur additional expense if the actual forfeiture rate is lower than originally estimated. A recovery of prior expense will be recorded if the actual rate is higher than originally estimated.

The following table presents all share-based compensation costs recognized in our statements of operations as part of selling, general and administrative expenses:

	Three Months Ended March 31,				Nine months ended March 31,
	2008		2007		2008		2007
	Fair Value		Fair Value		Fair Value		Fair Value
Method used to account for share-based compensation
Share based compensation
Stock options	$	236,876	$	314,815	$	656,628	$	828,097
Employee stock purchase plan	$	5,522	$	18,006	$	20,389	$	28,771
Restricted stock	$	42,889	$	—	$	91,905	$	—
Tax benefit at effective rate	$	27,032	$	46,940	$	81,095	$	140,821

Options outstanding that have vested and are expected to vest as of March 31, 2008 are as follows:

	Awards	Weighted -Average Exercise Price		Aggregate Intrinsic Value		Weighted Average Remaining Contractual Life
Options vested	850,142	$	10.50	$	3,280	6.1
Options expected to vest	769,774	$	4.68	$	—	9.1
Total vested and expected to vest	1,619,916	$	7.73	$	3,280	7.6

Restricted stock that has vested and is expected to vest as of March 31, 2008 is as follows:

	Awards	Aggregate Intrinsic Value
Restricted stock vested	74,464	$	177,969
Restricted stock expected to vest	134,800	$	322,172
Total vested and expected to vest	209,264	$	500,141

A summary of award activity under the Plans as of March 31, 2008 and 2007, and changes during the nine months then ended, is presented below:

	Incentive Stock Options						Nonqualified Stock Options
						Weighted					Weighted
		Weighted-				Average		Weighted-			Average
		Average		Aggregate		Remaining		Average		Aggregate	Remaining
		Exercise		Intrinsic		Contractual		Exercise		Intrinsic	Contractual
	Awards	Price		Value		Life	Awards	Price		Value	Life

Outstanding at July 1, 2007	501,349	$	7.48				617,982	$	11.00
Granted	462,918	$	4.03				85,082	$	4.03
Exercised	—	—					—	—
Forfeited or expired	6,900	$	5.67				—	—
Outstanding at March 31, 2008	957,367	$	5.83	$	3,280	8.2	703,064	$	10.16	—	6.8

Outstanding at March 31, 2008 and not yet vested	626,638	$	4.57	—		9.2	183,651	$	5.05	—	8.9
Exercisable at March 31, 2008	330,729	$	8.21	$	3,280	6.3	519,413	$	11.96	—	6.0

	Incentive Stock Options						Nonqualified Stock Options
						Weighted						Weighted
		Weighted-				Average		Weighted-				Average
		Average		Aggregate		Remaining		Average		Aggregate		Remaining
		Exercise		Intrinsic		Contractual		Exercise		Intrinsic		Contractual
	Awards	Price		Value		Life	Awards	Price		Value		Life

Outstanding at July 1, 2006	307,541	$	8.47				484,462	$	12.42
Granted	220,263	$	6.14				133,520	$	5.84
Exercised	375	$	0.75	$	2,063		—	—
Forfeited or expired	12,980	$	10.56				—	—
Outstanding at March 31, 2007	514,449	$	7.42	$	59,876	8.1	617,982	$	11.00	$	36,000	7.4

Outstanding at March 31, 2007 and not yet vested	297,121	$	6.41	$	36,451	9.2	224,258	$	8.20	$	36,000	8.8
Exercisable at March 31, 2007	217,328	$	8.80	$	23,425	6.5	393,724	$	12.60	$	—	6.6

	Restricted Stock
		Aggregate
		Intrinsic
	Awards	Value

Outstanding at July 1, 2007	—	—
Granted	209,264	$	843,334
Forfeited or expired	—	—
Outstanding at March 31, 2008	209,264	$	500,141
Unvested at March 31, 2008	134,800	$	322,172
Vested at March 31, 2008	74,464	$	177,969

Options with a fair value of approximately $646,000 vested during the nine months ended March 31, 2008. As of March 31, 2008, there was approximately $1,556,000 of total unrecognized compensation cost related to nonvested share-based compensation awards granted under the Plans. That cost is expected to be recognized over a weighted average period of 1.6 years. As of March 31, 2007, there was approximately $1,429,000 of total unrecognized compensation cost related to nonvested share-based compensation awards granted under the Plans.

Unearned Grant Funds – The Company records all grant funds received as a liability until the Company fulfills all the requirements of the grant funding program.

Loss per Common Share – SFAS No. 128, Earnings per Share, requires a dual presentation of basic and diluted earnings per share on the face of the Company’s consolidated statement of operations and a reconciliation of the computation of basic earnings per share to diluted earnings per share. Basic earnings per share excludes the dilutive impact of common stock equivalents and is computed by dividing net income by the weighted-average number of shares of common stock outstanding for the period. Diluted earnings per share include the effect of potential dilution from the exercise of outstanding common stock equivalents into common stock using the treasury stock method; such items would not be considered for diluted loss per share due to their antidilutive effects. Earnings per share amounts for all periods presented have been calculated in accordance with the requirements of SFAS No. 128. A reconciliation of the Company’s basic and diluted loss per share follows:

	Three Months Ended March 31,
	2008				2007
	Net Loss			Shares	Net Loss			Shares
	(Numerator)			(Denominator)	(Numerator)			(Denominator)

Basic loss per share factors	$	(1,255,845	)	24,268,449	$	(6,607,359	)	24,164,385

Effect of potentially dilutive option and restricted stock plans	—			—	—			—
Diluted loss per share factors	$	(1,255,845	)	24,268,449	$	(6,607,359	)	24,164,385

Basic loss per share	$	(0.05	)		$	(0.27	)
Diluted loss per share	$	(0.05	)		$	(0.27	)

The number of anti-dilutive shares that have been excluded in the computation of diluted loss per share for the three months ended March 31, 2008 and 2007 were 1,915,231 and 1,132,431, respectively.

	Nine Months Ended March 31,
	2008				2007
	Net Loss			Shares	Net Loss			Shares
	(Numerator)			(Denominator)	(Numerator)			(Denominator)

Basic loss per share factors	$	(2,040,553	)	24,208,830	$	(4,354,162	)	24,155,556

Effect of potentially dilutive option and restricted stock plans	—			—	—			—
Diluted loss per share factors	$	(2,040,553	)	24,208,830	$	(4,354,162	)	24,155,556

Basic loss per share	$	(0.08	)		$	(0.18	)
Diluted loss per share	$	(0.08	)		$	(0.18	)

The number of anti-dilutive shares that have been excluded in the computation of diluted loss per share for the nine months ended March 31, 2008 and 2007 were 1,915,231 and 1,132,431, respectively.

Note 3. New Accounting Standards

In July 2006, the FASB issued Interpretation No. 48, “Accounting for Uncertainty in Income Taxes” (FIN 48), to clarify the accounting for uncertainty in income taxes recognized in an enterprise’s financial statements in accordance with SFAS 109, “Accounting for Income Taxes.” Effective for tax years beginning after December 15, 2006, FIN 48 prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Under FIN 48, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. FIN 48 also provides guidance on derecognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, and income tax disclosures. Upon adoption, we recognized a $40,000 increase in beginning deferred tax asset and increase in accrued liabilities related to FIN 48. See Note 16 – Income Taxes.

In May 2007, the FASB issued FASB Staff Position No. FIN 48-1, “Definition of Settlement in FASB Interpretation No. 48.” This FASB Staff Position (FSP) amends FASB Interpretation No. 48, “Accounting for Uncertainty in Income Taxes,” to provide guidance on how an enterprise should determine whether a tax position is effectively settled for the purpose of recognizing previously unrecognized tax benefits. This guidance, effective immediately, will be applicable to the Company upon completion of an audit or examination by a taxing authority. The adoption of this guidance has had no affect on the Company’s financial position in the current year.

In December 2007, the FASB issued SFAS No. 141 (revised 2007), “Business Combinations” which replaces SFAS 141 but retains the fundamental concept of purchase method of accounting in a business combination and improves reporting by creating greater consistency in the accounting and financial reporting of business combinations, resulting in more complete, comparable, and relevant information for investors and other users of financial statements. To achieve this goal, the new standard requires the acquiring entity in a business combination to recognize all the assets acquired and liabilities assumed in the transaction and any noncontrolling interest at the acquisition date measured at their fair value as of that date. This statement requires measuring the noncontrolling interest in the acquiree at fair value which will result in recognizing the goodwill attributable to

the noncontrolling interest in addition to that attributable to the acquirer. This statement also requires the recognition of assets acquired and liabilities assumed arising from contractual contingencies as of the acquisition date, measured at their acquisition fair values. SFAS No. 141(R) is effective for the Company related to acquisitions occurring on or after July 1, 2009.

In December 2007, the FASB issued SFAS No. 160, “Noncontrolling Interests in Consolidated Financial Statements,” an amendment of ARB No. 51, which will affect only those entities that have an outstanding noncontrolling interest in one or more subsidiaries or that deconsolidate a subsidiary by requiring all entities to report noncontrolling (minority) interests in subsidiaries in the same way as equity in the consolidated financial statements. In addition, SFAS No. 160 eliminates the diversity that currently exists in accounting for transactions between an entity and noncontrolling interests by requiring they be treated as equity transactions. SFAS No. 160 is effective for fiscal years beginning after December 15, 2008 (for the Company, fiscal year beginning July 1, 2009). The Company is currently evaluating the impact of SFAS No. 160 on its financial position and results of operations.

In February 2007, the FASB issued SFAS No. 159 (“SFAS 159”), “The Fair Value Option for Financial Assets and Financial Liabilities,” providing companies with an option to report selected financial assets and liabilities at fair value. The Standard’s objective is to reduce both complexity in accounting for financial instruments and the volatility in earnings caused by measuring related assets and liabilities differently. Generally accepted accounting principles have required different measurement attributes for different assets and liabilities that can create artificial volatility in earnings. SFAS 159 helps to mitigate this type of accounting-induced volatility by enabling companies to report related assets and liabilities at fair value, which would likely reduce the need for companies to comply with detailed rules for hedge accounting. SFAS 159 also establishes presentation and disclosure requirements designed to facilitate comparisons between companies that choose different measurement attributes for similar types of assets and liabilities. The standard requires companies to provide additional information that will help investors and other users of financial statements to more easily understand the effect of the Company’s choice to use fair value on its earnings. It also requires entities to display the fair value of those assets and liabilities for which they have chosen to use fair value on the face of the balance sheet. SFAS 159 is effective for fiscal years beginning after November 15, 2007 (for the Company, fiscal year beginning July 1, 2008). We are currently evaluating the impact of adopting SFAS 159 on our financial statements.

In September 2006, the FASB issued SFAS No. 157, “Fair Value Measurements” (SFAS 157). This Statement defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles (GAAP), and expands disclosures about fair value measurements. This Statement applies under other accounting pronouncements that require or permit fair value measurements, the Board having previously concluded in those accounting pronouncements that fair value is the relevant measurement attribute. Accordingly, this Statement does not require any new fair value measurements. However, for some entities, the application of this Statement will change current practice. This Statement is effective for financial statements issued for fiscal years beginning after November 15, 2007 (for the Company, fiscal year beginning July 1, 2008), and interim periods within those fiscal years. The Company has not completed its study of the effects of adopting this standard.

In December 2007, the FASB ratified the consensus reached by the Emerging Issues Task Force on Issue No. 07-1, Accounting for Collaborative Arrangements (“EITF 07-1”), which is effective for fiscal years beginning after December 15, 2008 (for the Company, fiscal year beginning July 1, 2009). EITF 07-1 addresses entities entering into arrangements to participate in joint operating activity to, for example, jointly develop and commercialize a drug candidate. EITF 07-1 addresses how a company should report costs incurred and revenue generated from transactions with third parties should be reported by the participants of a collaborative arrangement, how an entity should characterize payments made between participants, and what participants should disclose in the notes to the financial statements. The Company is currently evaluating the impact of EITF 07-1 on its financial position and results of operations.

In June 2007, the FASB ratified the consensus reached by the Emerging Issues Task Force on Issue No. 07-3, Accounting for Advance Payments for Goods or Services Received for Use in Future Research and Development Activities (“EITF 07-3”), which is effective January 1, 2008 and is applied prospectively for new contracts entered into on or after the effective date. EITF 07-3 addresses nonrefundable advance payments for goods or services that will be used or rendered for future research and development activities. EITF 07-3 will require these payments be deferred and capitalized and recognized as an expense as the related goods are delivered or the related services are performed. The adoption of Issue No. 07-3 in the quarter ended March 31, 2008 has had little or no impact on the Company’s financial position or results of operations.

Note 4. Inventories

The Company values its inventory at the lower of cost (determined by the first-in, first-out method) or market, regularly reviews inventory quantities on hand, and records a provision for excess and obsolete inventory based primarily on estimated forecasts of product demand and production requirements. The Company’s estimates of future product demand may fluctuate, in which case estimated required reserves for excess and obsolete inventory may increase or decrease. If the Company’s inventory is determined to be overvalued, the Company recognizes such costs in cost of goods sold at the time of such determination.

Inventories consist of the following:

	March 31, 2008		June 30, 2007

Raw materials	$	3,695,712	$	3,631,780
Work-in-process	1,052,105		1,008,195
Finished goods	6,989,541		9,640,106
Packaging supplies	281,057		238,403
	$	12,018,415	$	14,518,484

The preceding amounts are net of inventory reserves of $954,086 and $923,920 at March 31, 2008 and June 30, 2007, respectively.

Note 5. Property, Plant and Equipment

Property, plant and equipment are stated at cost. Depreciation is provided for by the straight-line and accelerated methods over the estimated useful lives of the assets. Depreciation expense for the three months ended March 31, 2008 and 2007 was approximately $768,000 and $690,000, respectively. Depreciation expense for the nine months ended March 31, 2008 and 2007 was approximately $2,641,000 and $1,982,000, respectively. Property, plant and equipment consist of the following:

		March 31,			June 30,
	Useful Lives	2008			2007
Land	—	$	918,314		$	918,314
Building and improvements	10 - 39 years	16,188,931			16,229,427
Machinery and equipment	5 - 10 years	21,365,851			21,275,686
Furniture and fixtures	5 - 7 years	837,262			837,262
		$	39,310,358		$	39,260,689
		(14,224,639		)	(11,817,528		)
		$	25,085,719		$	27,443,161

As of March 31, 2008, $1,756,087 of property, plant and equipment ($1,805,158, net of $49,071 of accumulated depreciation) was pledged by the Company as collateral for a mortgage, the balance of which was $1,751,446 as of March 31, 2008.

Note 6. Investment Securities - Available-for-Sale

The amortized cost, gross unrealized gains and losses, and fair value of the Company’s available-for-sale securities are summarized as follows:

March 31, 2008

Available-for-Sale

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value

U.S. Government Agency	$	1,803,757	$	76,209	$	—		$	1,879,966
Asset-Backed Securities	643,254		3,901		(24,366		)	622,789
	$	2,447,011	$	80,110	$	(24,366	)	$	2,502,755

June 30, 2007

Available-for-Sale

	Amortized Cost		Gross Unrealized Gains		Gross Unrealized Losses			Fair Value

U.S. Government Agency	$	2,474,435	$	8,302	$	(5,525	)	$	2,477,212
Asset-Backed Securities	892,168		18		(48,766		)	843,420
	$	3,366,603	$	8,320	$	(54,291	)	$	3,320,632

The amortized cost and fair value of the Company’s current available-for-sale securities by contractual maturity at March 31, 2008 are summarized as follows:

	March 31, 2008				June 30, 2007
	Available for Sale				Available for Sale
	Amortized		Fair		Amortized		Fair
	Cost		Value		Cost		Value
Due in one year or less	$	—	$	—	$	201,540	$	198,750
Due after one year through five years	1,965,326		2,038,854		2,491,286		2,493,953
Due after five years through ten years	132,760		134,392		216,182		208,602
Due after ten years	348,925		329,509		457,595		419,327
	$	2,447,011	$	2,502,755	$	3,366,603	$	3,320,632

The Company uses the specific identification method to determine the cost of securities sold. There were no securities held from a single issuer that represented more than a 10% ownership interest.

The table below indicates the length of time individual securities have been in a continuous unrealized loss position as of March 31, 2008:

	March 31, 2008
	Number	Less than 12 months				12 months or longer					Total
Description of	of	Fair		Unrealized		Fair		Unrealized			Fair		Unrealized
Securities	Securities	Value		Loss		Value		Loss			Value		Loss

U.S. Government Agency	0	$	—	$	—	$	—	$	—		$	—	$	—
Asset-Backed Securities	6	—		—		189,559		(24,366		)	189,559		(24,366		)
Total tempory impaired
investment securities	6	$	—	$	—	$	189,559	$	(24,366	)	$	189,559	$	(24,366	)

The investment securities shown above currently have fair values less than amortized cost and therefore contain unrealized losses. The Company has evaluated these securities and has determined that the decline in value is not related to any company or industry specific event. At March 31, 2008, there were approximately 6 out of 27 investment securities with unrealized losses. The Company anticipates full recovery of amortized costs with respect to these securities at maturity or sooner in the event of a more favorable market interest rate environment. Realized gains and losses from sale of investment securities have been immaterial for the three months and nine months ended March 31, 2008 and 2007.

Note 7. Bank Line of Credit

The Company has a $3 million line of credit from Wachovia Bank, N.A. that bears interest at the prime interest rate less 0.25% (5.25% at March 31, 2008). The Company currently has $2,083,000 available under this line of credit. The Company has entered into a letter of credit for $917,000 with a supplier which has reduced the amount available under the line of credit. The line of credit was renewed and extended to November 30, 2009. The line of credit is collateralized by substantially all of the Company’s assets. The agreement contains covenants with respect to working capital, net worth and certain ratios, as well as other covenants.

Note 8. Unearned Grant Funds

In July 2004, the Company received $500,000 of grant funding from the Commonwealth of Pennsylvania, acting through the Department of Community and Economic Development. The grant funding program requires the Company to use the funds for machinery and equipment located at their Pennsylvania locations, hire an additional 100 full-time employees by June 30, 2006, operate its Pennsylvania locations a minimum of five years and meet certain matching investment requirements. The Company complied with two of the three requirements above and the requirement to operate its Pennsylvania locations is still ongoing, however, the Company failed to comply with hiring an additional 100 full-time employees. The Company is currently providing information to the Department of Community and Economic Development to grant an extension or waive the obligation of hiring an additional 100 full-time employees. The Company will be liable to repay the full amount of the grant funding ($500,000) if an extension or waiver is not received. The Company records the unearned grant funds as a liability until the Company complies with all of the requirements of the grant funding program. On a quarterly basis, the Company monitors its progress in fulfilling the requirements of the grant funding program and will determine the status of the liability. As of March 31, 2008, the grant funding is recognized as a short term liability under the caption of Unearned Grant Funds, since the Company has not yet met the requirement to add 100 full-time employees.

Note 9. Long-Term Debt

Long-term debt consists of the following:

	March 31,		June 30,
	2008		2007
PIDC Regional Center, LP III loan	$	4,500,000	$	4,500,000
Pennsylvania Industrial Development Authority loan	1,093,732		1,150,212
Pennsylvania Department of Community & Economic Development loan	308,200		388,487
Tax-exempt bond loan (PAID)	905,000		904,422
Equipment loan	481,876		722,266
SBA loan	196,497		231,812
First National Bank of Cody	1,751,446		1,782,766

Total debt	9,236,751		9,679,965
Less current portion	703,570		692,119

Long term debt	$	8,533,181	$	8,987,846

Current Portion of Long Term Debt

	March 31,		June 30,
	2008		2007
PIDC Regional Center, LP III loan	$	—	$	—
Pennsylvania Industrial Development Authority loan	72,628		70,604
Pennsylvania Department of Community & Economic Development loan	99,926		97,001
Tax-exempt bond loan (PAID)	110,000		109,164
Equipment loan	320,520		320,520
SBA loan	52,869		49,647
First National Bank of Cody	47,627		45,183

Total current portion of long term debt	$	703,570	$	692,119

The Company financed $4,500,000 through the Philadelphia Industrial Development Corporation (PIDC). The Company will pay a bi-annual interest payment at a rate equal to two and one-half percent per annum. The outstanding principal balance shall be due and payable 5 years (60 months) from January 1, 2006.

The Company financed $1,250,000 through the Pennsylvania Industrial Development Authority (PIDA). The Company is required to make equal payments each month for 180 months starting February 1, 2006 with interest of two and three-quarter percent per annum.

An additional $500,000 was financed through the Pennsylvania Department of Community and Economic Development Machinery and Equipment Loan Fund. The Company is required to make equal payments for 60 months starting May 1, 2006 with interest of two and three quarter percent per annum.

In April 1999, the Company entered into a loan agreement (the “Agreement”) with a governmental authority, the Philadelphia Authority for Industrial Development (the “Authority” or “PAID”), to finance future construction

and growth projects of the Company. The Authority issued $3,700,000 in tax-exempt variable rate demand and fixed rate revenue bonds to provide the funds to finance such growth projects pursuant to a trust indenture (“the Trust Indenture”). A portion of the Company’s proceeds from the bonds was used to pay for bond issuance costs of approximately $170,000. The Trust Indenture requires that the Company repay the Authority loan through installment payments beginning in May 2003 and continuing through May 2014, the year the bonds mature. The bonds bear interest at the floating variable rate determined by the organization responsible for selling the bonds (the “remarketing agent”). The interest rate fluctuates on a weekly basis. The effective interest rate at March 31, 2008 was 3.6%.

The Equipment Loan consists of a term loan with a maturity of five years. The Company, as part of the 2003 Loan Financing agreement with Wachovia, is required to make equal payments of principal plus interest.

The financing facilities under the 2003 Loan Financing, of which only the Equipment Loan is left, bear interest at a variable rate equal to the LIBOR rate plus 150 basis points. The LIBOR rate is the rate per annum, based on a 30-day interest period, quoted two business days prior to the first day of such interest period for the offering by leading banks in the London interbank market of dollar deposits. As of March 31, 2008, the interest rate for the 2003 Loan Financing (of which only the Equipment loan remains) was 4.62%.

The Company has executed Security Agreements with Wachovia, PIDA and PIDC in which the Company has agreed to pledge substantially all of its assets to collateralize the amounts due.

The terms of the Equipment Loan require that the Company meet certain financial covenants and reporting standards, including the attainment of standard financial liquidity and net worth ratios.

Included in the acquisition of Cody was a loan from the Small Business Administration (“SBA”). The loan requires fixed monthly payments, with an effective interest rate of 8.75%, through July 31, 2012.

Also as part of the Cody acquisition, the Company became primary beneficiary to a variable interest entity (“VIE”) called Cody LCI Realty, LLC. See Note 17, Consolidation of Variable Interest Entity for additional description. The VIE owns land and a building which is being leased to Cody. A mortgage loan with First National Bank of Cody has been consolidated in the Company’s financial statements, along with the related land and building. The mortgage has 19 years remaining. Principal and interest payments of $14,782, at a fixed interest rate of 7.5%, are being made on a monthly basis through June 2026. The mortgage loan is collateralized by the land and building.

Long-term debt amounts due, for the twelve month periods ended March 31 are as follows:

Twelve	Amounts Payable
Month Periods	to Institutions

2008	$	703,570
2009	562,721
2010	4,925,541
2011	291,471
2012	280,291
Thereafter	2,473,157

	$	9,236,751

Note 10. Contingencies

The Company monitors its compliance with all environmental laws. Any compliance costs which may be incurred are contingent upon the results of future site monitoring and will be charged to operations when incurred.

Contingent consideration of 120,000 shares of Lannett common stock was offered as part of the April 10, 2007 acquisition of Cody Laboratories, Inc. In accordance with the agreement, the contingent shares of unregistered Lannett common stock are issuable upon Cody Labs receiving a license from a regulatory agency. To date, this license has not been granted.

In addition to the matters reported herein, the Company is involved in litigation which arises in the normal course of business. In the opinion of management, the resolution of these lawsuits will not have a material adverse effect on the consolidated financial position or results of operations.

Note 11. Commitments

Leases

In June 2006, Lannett signed a lease agreement on a 66,000 square foot facility located on seven acres in Philadelphia. An additional agreement which gives the Company the option to buy the facility was also signed. This facility is initially going to be used for warehouse space with the expectation of making this facility the Company’s headquarters in addition to manufacturing and warehousing. The other Philadelphia locations will continue to be utilized as manufacturing, packaging, and as a research laboratory. This gives Lannett the space to fit its desire to expand.

Lannett’s subsidiary, Cody Laboratories, Inc. (“Cody”) leases a 73,000 square foot facility in Cody, Wyoming. This location houses Cody’s manufacturing and production facilities. Cody leases the facility from Cody LCI Realty, LLC, a Limited Liability Company which is 50% owned by Lannett. See Note 17. Because Cody LCI Realty, LLC, is consolidated in the Company’s financial statements, all intercompany rent is eliminated in consolidation.

In addition to the above, the Company has operating leases, expiring in 2008, for office equipment.

Rental and lease expense for the three months ended March 31, 2008 and 2007 was approximately $109,000 and $79,000, respectively and for the nine months ended March 31, 2008 and 2007 was approximately $339,000, and $194,000, respectively.

Contractual Obligations

The following table represents annual debt, lease and contractual purchase obligations as of March 31, 2008:

	Total		Less than 1 year		1-3 years		3-5 years		more than 5 years

Long-Term Debt	$	9,236,751	$	703,570	$	5,488,262	$	571,762	$	2,473,157
Operating Leases	1,528,013		470,628		868,523		188,862		—
Purchase Obligations	135,000,000		19,000,000		41,000,000		45,000,000		30,000,000
Interest on Obligations	2,104,198		293,109		607,447		364,967		838,675
Total	$	147,868,962	$	20,467,307	$	47,964,232	$	46,125,591	$	33,311,832

The purchase obligations above are due to the agreement with Jerome Stevens Pharmaceuticals, Inc. If the minimum purchase requirement is not met, Jerome Stevens has the right to terminate the contract within 60 days of Lannett’s failure to meet the requirement. If Jerome Stevens terminates the contract, Lannett does not pay any fee, but could lose its exclusive distribution rights in the United States. If Lannett’s management believes that it is not in the Company’s best interest to fulfill the minimum purchase requirements, it can also terminate the contract without any penalty. No matter which party terminates the purchase agreement, there would be minimal impact on the operating cash flows of the Company from the termination.

Employment Agreements

The Company has entered into employment agreements with Arthur P. Bedrosian, President and Chief Executive Officer, Brian Kearns, Chief Financial Officer, Secretary, Treasurer, Kevin Smith, Vice President of Sales and Marketing, Bernard Sandiford, Vice President of Operations, and William Schreck, Vice President of Logistics, (the “Named Executives”). Each of the agreements provide for an annual base salary and eligibility to receive a bonus. The salary and bonus amounts of the Named Executives are determined by the Board of Directors. Additionally, the Named Executives are eligible to receive stock options, which are granted at the discretion of the Board of Directors, and in accordance with the Company’s policies regarding stock option grants.

Under the agreements, the Named Executive employees may be terminated at any time with or without cause, or by reason of death or disability. In certain termination situations, the Company is liable to pay severance compensation to the Named Executive of between one year and three years.

Note 12. Other Comprehensive Loss

The Company’s other comprehensive loss is comprised of unrealized gains on investment securities classified as available-for-sale. The components of comprehensive loss and related taxes consisted of the following as of March 31, 2008 and 2007:

	For the Three Months Ended March 31,						For the Nine Months Ended March 31,
	2008			2007			2008			2007
Unrealized Holding Gain on Securities	$	71,315		$	3,173		$	101,715		$	104,621
Tax at Effective Rate	(28,526		)	(1,269		)	(40,686		)	(41,848		)
Total Unrealized Gain on Securities, Net	42,789			1,904			61,029			62,773
Total Other Comprehensive Income	42,789			1,904			61,029			62,773
Net Loss	(1,255,845		)	(6,607,359		)	(2,040,553		)	(4,354,162		)

Total Comprehensive Loss	$	(1,213,056	)	$	(6,605,455	)	$	(1,979,524	)	$	(4,291,389	)

Note 13. Employee Benefit Plan

The Company has a defined contribution 401k plan (the “Plan”) covering substantially all employees. Pursuant to the Plan provisions, the Company is required to make matching contributions equal to 50% of each employee’s contribution, but not to exceed 4% of the employee’s compensation for the Plan year. Contributions to the Plan during the nine months ended March 31, 2008 and 2007 were $265,000 and $298,000, respectively.

Note 14. Employee Stock Purchase Plan

In February 2003, the Company’s shareholders approved an Employee Stock Purchase Plan (“ESPP”). Employees eligible to participate in the ESPP may purchase shares of the Company’s stock at 85% of the lower of the fair market value of the common stock on the first day of the calendar quarter, or the last day of the calendar quarter. Under the ESPP, employees can authorize the Company to withhold up to 10% of their compensation during any quarterly offering period, subject to certain limitations. The ESPP was implemented on April 1, 2003 and is qualified under Section 423 of the Internal Revenue Code. The Board of Directors authorized an aggregate total of 1,125,000 shares of the Company’s common stock for issuance under the ESPP. As of March 31, 2008, 100,960 shares have been issued under the ESPP. Compensation expense of $5,522 and $18,006 has been recognized for the three months ended March 31, 2008 and 2007, respectively, relating to the ESPP. Compensation expense of $20,389 and $28,771 has been recognized for the nine months ended March 31, 2008 and 2007, respectively, relating to the ESPP.

Note 15. Long-Term Incentive Plan (The “LTIP”)

In 2007, the shareholders of the Company approved the 2007 Long-term Incentive Plan (The “LTIP”). The purpose of the LTIP is to enable management of the Company to (i) own shares of stock in the Company, (ii) participate in the shareholder value which has been created, (iii) have a mutuality of interest with other shareholders and (iv) enable the Company to attract, retain and motivate key management level employees of particular merit. The LTIP authorizes the Compensation Committee of the Board of Directors to grant both stock and/or cash-based awards through (i) incentive and non-qualified stock options and/or (ii) restricted stock, and/or long-term performance awards to participants. With respect to the stock options and stock grants, 2,500,000 shares will be set aside for stock option grants and/or restricted stock awards.

During the nine months ended March 31, 2008, there were 209,264 total restricted shares awarded on September 18, 2007. Of these shares, 74,464 shares vested on January 1, 2008 and the remaining 134,800 shares vest over the next three years. There were no other restricted shares awarded during the period ended March 31, 2008. Zero and

548,000 options were issued under the LTIP during the three and nine months ended March 31, 2008, respectively.

Note 16. Income Taxes

The Company uses the liability method specified by Statement of Financial Accounting Standards No. 109 (FAS 109), Accounting for Income Taxes. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates which will be in effect when these differences reverse. Deferred tax expense/(benefit) is the result of changes in deferred tax assets and liabilities.

The provision for federal, state and local income taxes for the three months ended March 31, 2008 and 2007 was a tax benefit of approximately $615,000 and approximately $819,000, respectively, with effective tax rates of 33% and 11%, respectively. The provision for federal, state and local income taxes for the nine months ended March 31, 2008 and 2007 was a tax benefit of approximately $821,000 and expense of approximately $686,000, respectively, with effective tax rates of 29% and (19%), respectively. The tax rate for the periods ended March 31, 2008 is lower than 2007 due to permanent differences between tax and book income and loss.

On July 1, 2007, we adopted the provisions of FIN 48, Accounting for Uncertainty in Income Taxes — an interpretation of FASB Statement No. 109, which provides a financial statement recognition threshold and measurement attribute for a tax position taken or expected to be taken in a tax return. Under FIN 48, we may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position should be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. FIN 48 also provides guidance on de-recognition of income tax assets and liabilities, classification of current and deferred income tax assets and liabilities, accounting for interest and penalties associated with tax positions, and income tax disclosures.

As a result of the implementation of adopting FIN 48, the Company increased the liability for unrecognized tax benefits by $40,000 in the first quarter of Fiscal 2008. The Company recognizes interest accrued on unrecognized tax benefits in interest expense and any related penalties in operating expenses.

The Company files tax returns in the United States federal jurisdiction, Pennsylvania and New Jersey. The Company’s tax returns for years prior to 2003 generally are no longer subject to review as such years generally are closed. The Company is not currently involved with any reviews by any taxing authorities. The Company believes that an unfavorable resolution for open tax years would not be material to the financial position of the Company.

The Company adjusted the original purchase price allocation for Cody Labs, as a result of a study and additional analysis of assets acquired. The result of this study was to increase the deferred tax assets by $1,255,000 and decrease the value of Cody Labs’ property, plant and equipment by the same amount. This was done in accordance with Statement of Financial Accounting Standards No. 141 (revised 2007), Business Combinations.

Note 17. Consolidation of Variable Interest Entity

Lannett consolidates any Variable Interest Entity (“VIE”) of which we are the primary beneficiary. The liabilities recognized as a result of consolidating a VIE do not represent additional claims on our general assets; rather, they represent claims against the specific assets of the consolidated VIE. Conversely, assets recognized as a result of consolidating a VIE do not represent additional assets that could be used to satisfy claims against our general assets. Reflected in the March 31, 2008 and June 30, 2007 balance sheets are consolidated VIE assets of

approximately $1.8 million, which is comprised mainly of land and building. VIE liabilities consist of a mortgage on that property in the amount of approximately $1.8 million.

Cody LCI Realty LLC (“Realty”) is the only VIE that is consolidated. Realty has been consolidated by Cody prior to its acquisition by Lannett. Realty is a 50/50 joint venture between a former shareholder of Cody Labs and Lannett. Its purpose was to acquire the facility used by Cody. Until the acquisition of Cody in April 2007, Lannett had not consolidated the VIE because Cody Labs had been the primary beneficiary of the VIE. The risks associated with our interests in this VIE is limited to a decline in the value of the land and building as compared to the balance of the mortgage note on that property, up to Lannett’s 50% share of the venture. Realty owns the land and building, and Cody leases the building and property from Realty for $15,000 per month. All intercompany rent expense is eliminated upon consolidation with Cody.

The Company is not involved in any other variable interest entity.

Note 18. Related Party Transactions

The Company had sales of approximately $418,000 and $630,000 during the nine months ended March 31, 2008 and 2007, respectively, to a distributor (the “related party”) owned by Jeffrey Farber. Mr. Farber is a member of the Board of Directors, as well as the son of William Farber, who is the Chairman of the Board and principal shareholder of the Company. Accounts receivable includes amounts due from the related party of approximately $87,000 and $171,000 at March 31, 2008 and 2007, respectively. In management’s opinion, the terms of these transactions were not more favorable to the related party than they would have been to a non-related party.

In January 2005, Lannett Holdings, Inc. entered into an agreement in which the Company purchased for $100,000 and future royalty payments the proprietary rights to manufacture and distribute a product for which Pharmeral, Inc. owned the ANDA. In Fiscal 2008, the Company obtained FDA approval to use the proprietary rights. Accordingly, the Company has capitalized this purchased product right as an indefinite lived intangible asset and will test this asset for impairment on a quarterly basis. Arthur Bedrosian, President of the Company, Inc. was formerly the President and Chief Executive Officer and currently owns 100% of Pharmeral, Inc. This transaction was approved by the Board of Directors of the Company and in their opinion the terms were not more favorable to the related party than they would have been to a non-related party.

The Company has approximately $1,177,000 of deferred revenue as a result of prepayments on inventory received from Provell Pharmaceuticals, LLC (“Provell”). Provell is a joint venture to distribute pharmaceutical products through mail order outlets. Lannett was given 33% ownership of this venture in exchange for access to Lannett’s drug providers. The investment is valued at zero, due to losses incurred to date by Provell.

Note 19. Material Contract with Supplier

Jerome Stevens Pharmaceuticals agreement:

The Company’s primary finished product inventory supplier is Jerome Stevens Pharmaceuticals, Inc. (JSP), in Bohemia, New York. Purchases of finished goods inventory from JSP accounted for approximately 77% and 70% of the Company’s inventory purchases during the three and nine month periods ended March 31, 2008 and 32% and 52% during the three and nine month periods ended March 31, 2007. On March 23, 2004, the Company entered into an agreement with JSP for the exclusive distribution rights in the United States to the current line of JSP products, in exchange for four million (4,000,000) shares of the Company’s common stock. The JSP products covered under the agreement included Butalbital, Aspirin, Caffeine with Codeine Phosphate capsules, Digoxin tablets and Levothyroxine Sodium tablets, sold generically and under the brand name Unithroid®. The term of the agreement is ten years, beginning on March 23, 2004 and continuing through March 22, 2014. Both Lannett and JSP have the right to terminate the contract if one of the parties does not cure a material breach of the contract within thirty (30) days of notice from the non-breaching party.

During the term of the agreement, the Company is required to use commercially reasonable efforts to purchase minimum dollar quantities of JSP’s products being distributed by the Company. The minimum quantity to be purchased in the first year of the agreement is $15 million. Thereafter, the minimum quantity to be purchased increases by $1 million per year up to $24 million for the last year of the ten-year contract. The Company has met the minimum purchase requirement for the first four years of the contract, but there is no guarantee that the Company will be able to continue to do so in the future. If the Company does not meet the minimum purchase requirements, JSP’s sole remedy is to terminate the agreement.

Under the agreement, JSP is entitled to nominate one person to serve on the Company’s Board of Directors (the “Board”) provided, however, that the Board shall have the right to reasonably approve any such nominee in order to fulfill its fiduciary duty by ascertaining that such person is suitable for membership on the board of a publicly traded corporation. Suitability is determined by, but not limited to, the requirements of the Securities and Exchange Commission, the American Stock Exchange, and other applicable laws, including the Sarbanes-Oxley Act of 2002. As of March 31, 2008, JSP has not exercised the nomination provision of the agreement. The agreement was included as an Exhibit in the Current Report on Form 8-K filed by the Company on May 5, 2004, as subsequently amended.

Management determined that the intangible product rights asset created by this agreement was impaired as of March 31, 2005. Refer to Form 10K dated June 30, 2007, Note 1– intangible assets for additional disclosure and discussion of this impairment.

Other agreements:

In August 2005, the Company signed an agreement with a finished goods provider to purchase, at fixed prices, and distribute a certain generic pharmaceutical product in the United States. Purchases of finished goods inventory from this provider accounted for approximately 12% and 15% of the Company’s inventory purchases during the three and nine month periods ended March 31, 2008. Purchases of finished goods inventory from this provider accounted for approximately 25% and 20% of the Company’s inventory purchases during the three and nine month periods ended March 31, 2007. The term of the agreement is three years, beginning on August 22, 2005 and continuing through August 21, 2008.

During the term of the agreement, the Company has committed to provide a rolling twelve month forecast of the estimated Product requirements to this provider. The first three months of the rolling twelve month forecast are binding and constitute a firm order.

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS.

Introduction

The following information should be read in conjunction with the consolidated financial statements and notes in Part I, Item 1 of this Quarterly Report and with Management’s Discussion and Analysis of Financial Condition and Results of Operations contained in the Company’s Annual Report on Form 10-K for the fiscal year ended June 30, 2007.

This Report on Form 10-Q and certain information incorporated herein by reference contain forward-looking statements which are not historical facts made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees and investors are cautioned that all forward looking statements involve risks and uncertainties, including but not limited to the impact of competitive products and pricing, product demand and market acceptance, new product development, the regulatory environment, including without limitation, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission. These statements are based on management’s current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements which speak only as of the date made. Lannett is under no obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Critical Accounting Policies

The discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amount of assets and liabilities, revenues and expenses, and related disclosure of contingent assets and liabilities at the date of our financial statements. Actual results may differ from these estimates under different assumptions or conditions.

Critical accounting policies are defined as those that are reflective of significant judgments and uncertainties, and potentially result in materially different results under different assumptions and conditions. We believe that our critical accounting policies include those described below.

Consolidation of Variable Interest Entity – The Company consolidates any Variable Interest Entity (“VIE”) of which we are the primary beneficiary. The liabilities recognized as a result of consolidating a VIE do not represent additional claims on our general assets; rather, they represent claims against the specific assets of the consolidated VIE. Conversely, assets recognized as a result of consolidating a VIE do not represent additional assets that could be used to satisfy claims against our general assets. Reflected in the March 31, 2008 balance sheet are consolidated VIE assets of $1.8 million, which is comprised mainly of land and building. There were no VIE assets at March 31, 2007. VIE liabilities consist of a mortgage on that property in the amount of $1.8 million. This VIE was initially consolidated by Cody, as Cody has been the primary beneficiary. Cody has then been consolidated within Lannett’s financial statements, due to the acquisition in April 2007 of Cody Labs by the Company.

Revenue Recognition – The Company recognizes revenue when its products are shipped, and when title and risk of loss have transferred to the customer and provisions for estimates, including rebates, promotional adjustments, price adjustments, returns, chargebacks, and other potential adjustments are reasonably determinable. Accruals

for these provisions are presented in the consolidated financial statements as rebates and chargebacks payable and reductions to net sales.

The change in the reserves for various sales adjustments may not be proportional to the change in sales because of changes in both the product mix and the customer mix. Increased sales to wholesalers will generally require additional rebates. Incentives offered to increase sales vary from product to product. Provisions for estimated rebates and promotional and other credits are estimated based on historical experience, estimated customer inventory levels, and contract terms. Provisions for other customer credits, such as price adjustments, returns, and chargebacks require management to make subjective judgments. Unlike branded innovator companies, Lannett does not use information about product levels in distribution channels from third-party sources, such as IMS Health and NDC Health, in estimating future returns and other credits. Lannett calculates a chargeback/rebate rate based on contractual terms with its customers and applies this rate to customer sales. The major variable affecting this rate is customer mix, and estimates of expected customer mix are based on historical experience and sales expectations. The chargeback/rebate reserve is reviewed on a monthly basis by management using several ratios and metrics. Lannett’s methodology for estimating reserves in the nine months ended March 31, 2008 has been consistent with previous periods.

The Company ships its products to the warehouses of its wholesale and retail chain customers. When the Company and a customer reach an agreement for the supply of a product, the customer will generally continue to purchase the product, stock its warehouse, and resell the product to its own customers. The customer will continually reorder the product as its warehouse is depleted. The Company generally has no minimum size orders for its customers. Additionally, most warehousing customers prefer not to stock excess inventory levels due to the additional carrying costs and inefficiencies created by holding excess inventory. As such, the Company’s customers continually reorder the Company’s products. It is common for the Company’s customers to order the same products on a monthly basis. For generic pharmaceutical manufacturers, it is critical to ensure that customers’ warehouses are adequately stocked with its products. This is important due to the fact that several generic competitors compete for the consumer demand for a given product. Availability of inventory ensures that a manufacturer’s product is considered. Otherwise, retail prescriptions would be filled with competitors’ products. For this reason, the Company periodically offers incentives to its customers to purchase its products. These incentives are generally up-front discounts off its standard prices at the beginning of a generic campaign launch for a newly-approved or newly-introduced product, or when a customer purchases a Lannett product for the first time. Customers generally inform the Company that such purchases represent an estimate of expected resales for a period of time. This period of time is generally up to three months. The Company records this revenue, net of any discounts offered and accepted by its customers at the time of shipment. The shelf-life of the Company’s products ranges from 18 months to 36 months from the time of manufacture. The Company monitors its customers’ purchasing trends to identify any significant lapses in purchasing activity. If the Company observes a lack of recent activity, inquiries will be made to such customer regarding the success of the customer’s resale efforts. The Company attempts to minimize any potential return (or shelf life issues) by maintaining an active dialogue with the wholesale customers.

Chargebacks – The provision is based upon contracted prices with customers, and the accuracy of this provision is affected by changes in product sales mix and delays in selling products through distributors. This is considered the most significant and complex estimate used in the recognition of revenue. The chargeback is initiated when the Company sells its products to “indirect customers” such as independent pharmacies, managed care organizations, hospitals, nursing homes, and group purchasing organizations. The Company enters into agreements with its indirect customers to establish pricing for certain products. The indirect customers then select wholesalers from which to purchase the products at these contractual prices.

Upon the sale of a product to a wholesaler, the Company will estimate the chargeback provision required, based upon estimated purchases by indirect customers, each of whom may have varying contracted prices. Once the actual sale to the indirect customer occurs, the wholesaler will request a chargeback credit from the Company. The chargeback is the difference between the contractual price with the indirect customer and the wholesaler’s

invoice price, if the price sold to the indirect customer is lower than the direct price to the wholesaler. The provision for chargebacks is based on expected sell-through levels by the Company’s wholesale customers to the indirect customers. As sales increase to the large wholesale customers, such as Cardinal Health, AmerisourceBergen, and McKesson, the reserve for chargebacks will also generally increase. The size of the chargeback increase depends on the product and customer mix, as different products and customers will have different chargeback rates determined by the contractual sales prices. The Company continually monitors the reserve for chargebacks and makes adjustments as appropriate. Since the chargeback is initiated upon the transfer or sale of the product from the wholesaler to the indirect customer, there is typically a delay in processing the chargeback, based on the time to sell the product. Thus, the estimated chargeback reserve at the time of sale may vary from actual, based on this time delay and the product sales mix going through each distributor. The Company closely monitors this activity to ensure the estimates accurately reflect actual activity.

Rebates – Rebates are offered to the Company’s key customers to promote customer loyalty and encourage greater product sales. These rebate programs provide customers with rebate credits upon attainment of pre-established volumes or attainment of net sales milestones for a specified period. Other promotional programs are incentive programs offered to the customers. At the time of shipment, the Company estimates reserves for rebates and other promotional credit programs based on the specific terms in each agreement. The reserve for rebates increases as sales to certain wholesale and retail customers increase. However, these rebate programs are tailored to the customers’ individual programs. Hence, the reserve will depend on the mix of customers that comprise such rebate programs.

Returns – Consistent with industry practice, the Company has a product returns policy that allows certain customers to return product within a specified period prior to and subsequent to the product’s lot expiration date in exchange for a credit to be applied to future purchases. The Company’s policy requires that the customer obtain approval from the Company for any qualifying return. The Company estimates its provision for returns based on historical experience, changes to business practices, and credit terms. While such experience has allowed for reasonable estimations in the past, history may not always be an accurate indicator of future returns. The Company continually monitors the provisions for returns and makes adjustments when management believes that actual product returns may differ from established reserves. Generally, the reserve for returns increases as net sales increase. The reserve for returns is included in the rebates and chargebacks payable account on the balance sheet.

Other Adjustments – Other adjustments consist primarily of price adjustments, also known as “shelf stock adjustments,” which are credits issued to reflect decreases in the selling prices of the Company’s products that customers have remaining in their inventories at the time of the price reduction. Decreases in selling prices are discretionary decisions made by management to reflect competitive market conditions. Amounts recorded for estimated shelf stock adjustments are based upon specified terms with direct customers, estimated declines in market prices, and estimates of inventory held by customers. The Company regularly monitors these and other factors and evaluates the reserve as additional information becomes available. Other adjustments are included in the rebates and chargebacks payable account on the balance sheet.

The following tables identify the reserves for each major category of revenue allowance and a summary of the activity for the nine months ended March 31, 2008 and 2007:

For the nine months ended March 31, 2008


Reserve Category	Chargebacks			Rebates			Returns			Other			Total

Reserve Balance as of June 30, 2007	$	4,649,478		$	871,339		$	113,313		$	52,234		$	5,686,364
Actual credits issued related to sales recorded in prior fiscal years	(4,429,923		)	(1,741,804		)	(146,917		)	—			(6,318,644		)
Reserves or (reversals) charged during Fiscal 2008 related to sales in prior fiscal years	—			870,465			50,000			(50,000		)	870,465
Reserves charged to net sales during Fiscal 2008 related to sales recorded in Fiscal 2008	17,985,506			6,240,517			2,200,267			473,423			26,899,713
Actual credits issued related to sales recorded in Fiscal 2008	(14,721,493		)	(4,988,844		)	(805,702		)	(473,552		)	(20,989,591		)
Reserve Balance as of March 31, 2008	$	3,483,568		$	1,251,673		$	1,410,961		$	2,105		$	6,148,307

For the nine months ended March 31, 2007


Reserve Category	Chargebacks			Rebates			Returns			Other			Total

Reserve balance as of June 30, 2006	$	10,137,400		$	2,183,100		$	416,000		$	275,600		$	13,012,100
Actual credits issued related to sales recorded in prior fiscal years	(10,170,000		)	(1,800,000		)	(890,000		)	(250,000		)	(13,110,000		)
Reserves or (reversals) charged during Fiscal 2007 related to sales in prior fiscal years	—			(300,000		)	460,000			—			160,000
Reserves charged to net sales during Fiscal 2007 related to sales recorded in Fiscal 2007	24,340,700			8,832,300			986,400			1,033,100			35,192,500
Actual credits issued related to sales recorded in Fiscal 2007	(17,065,500		)	(5,122,200		)	(954,700		)	(265,000		)	(23,407,400		)
Reserve Balance as of March 31, 2007	$	7,242,600		$	3,793,200		$	17,700		$	793,700		$	11,847,200

Credits issued during the quarter that relate to prior year sales are charged against the opening balance. In aggregate, additional reserves or reversals of reserves have historically offset each other. The table above shows the effects of reversals within the rebates, returns and other categories. It is the Company’s intention that all reserves be charged to sales in the period that the sale is recognized, however, due to the nature of this estimate, it is possible that the Company may sometimes need to increase or decrease the reserve based on prior period sales. If that were to occur, management would disclose that information at that time. If the historical data the Company uses and the assumptions management makes to calculate its estimates of future returns, chargebacks, and other credits do not accurately approximate future activity, its net sales, gross profit, net income and earnings per share could change. However, management believes that these estimates are reasonable based upon historical experience and current conditions.

In the second quarter of Fiscal 2008, the Company issued rebate credits to a customer arising from sales in the prior year. These rebates were submitted, approved and processed by the Company in the current year. The reserve table above shows approximately $870,000 as additional reserve charged during Fiscal 2008. During this quarter, new information was obtained which indicated that these items were in fact valid rebates, and that required the Company to deduct them from sales. As a result, the Company recorded additional rebates in the amount of approximately $870,000.

The rates of reserves will vary, as well as the category under which the credit falls. This variability comes about when the Company is working with indirect customers to compete with the pricing of other generic companies. The Company is currently working on improving computer systems to improve the accuracy of tracking and processing chargebacks and rebates. Improvements to automate calculation of reserves will not only reduce the potential for human error, but also will result in more in-depth analysis and improved customer interaction for resolution of open credits.

The rate of credits issued is monitored by the Company at least on a quarterly basis. The Company may change the estimate of future reserves based on the amount of credits processed, or the rate of sales made to indirect customers. The increase of reserves to $6,148,307 at March 31, 2008 from $5,686,364 at June 30, 2007 is due to the timing of credits being processed by the customers and by the Company. Approximately 96% of the reserve balance from June 30, 2007 has been processed through the third quarter of Fiscal 2008. Management estimates reserves based on sales mix. A comparison to wholesaler inventory reports is performed quarterly, in order to justify the balance of unclaimed chargebacks and rebates. The Company has historically found a direct correlation between the calculation of the reserve based on sales mix, and the wholesaler inventory analysis.

Accounts Receivable – The Company performs credit evaluations of its customers and adjusts credit limits based upon payment history and the customer’s current credit worthiness, as determined by a review of available credit information. The Company continuously monitors collections and payments from its customers and maintains a provision for estimated credit losses based upon historical experience and any specific customer collection issues that have been identified. While such credit losses have historically been within the both Company’s expectations and the provisions established, the Company cannot guarantee that it will continue to experience the same credit loss rates that it has in the past.

The Company also regularly monitors customer Accounts Receivable (AR) balances through a tool known as Days Sales Outstanding (“DSO”). This calculation for Net DSO begins with the Gross AR less the Rebates and Chargeback reserve. This net amount is then divided by the average daily net sales for the period. The table below shows the results of these calculations for the relevant periods.

	Nine months ended 3/31/08	Fiscal Year ended 6/30/07	Nine months ended 3/31/07
Net DSO (in days)	75	72	75
Gross DSO (in days)	63	74	79

The Gross DSO above shows the result of the same calculation without regard to rebates and chargebacks. The Company monitors both Net DSO and Gross DSO as an overall check on collections and reasonableness of reserves. In order to be effective indicators, both types of DSO are evaluated on a quarterly basis. The Gross DSO calculation provides management with an understanding of the frequency of customer payments, and the ability to process customer payments and deductions. The Net DSO calculation provides management with an understanding of the relationship of the A/R balance net of the reserve liability compared to net sales after reserves charged during the period.

The Company’s payment terms are consistent with the generic pharmaceutical industry at 60 days for payment from all customers, including wholesalers. Net DSO for the first nine months of Fiscal 2008, is consistent with prior net DSO calculations. Gross DSO for the first nine months of Fiscal 2008, decreased as a result of our ability to process customer payments and deductions in a timelier manner which, in turn, also reduced the reserve accruals. Management expects the DSO calculation normal levels to be 60 to 70 days. Significant variances greater or less than this range are reviewed and, if necessary, action is taken.

Inventories – The Company values its inventory at the lower of cost (determined by the first-in, first-out method) or market, regularly reviews inventory quantities on hand, and records a provision for excess and obsolete

inventory based primarily on estimated forecasts of product demand and production requirements. The Company’s estimates of future product demand may prove to be inaccurate, in which case it may have understated or overstated the provision required for excess and obsolete inventory. In the future, if the Company’s inventory is determined to be overvalued, the Company would be required to recognize such costs in cost of goods sold at the time of such determination.

Share-based Compensation – Statement of Financial Accounting Standards (“SFAS”) No. 123 (revised 2004), “Share-Based Payment,” (123(R)) was adopted effective July 1, 2005. Share-based compensation cost is measured using the Black-Scholes option pricing model. The following table highlights relevant stock-option plan information for the nine months ended:

	March 31, 2008		March 31, 2007
Share based compensation expense
Stock options	$	657,000	$	828,000
Employee stock purchase plan	$	20,000	$	29,000
Restricted stock	$	92,000	$	—
Total compensation cost related to non-vested awards not yet recognized	$	1,981,000	$	1,429,000
Weighted average period over which it is to be recognized	1.6 years		1.6 years

Results of Operations - Three months ended March 31, 2008 compared with three months ended March 31, 2007

Net sales for the three months ended March 31, 2008 (“Fiscal 2008”) decreased 18% to $16,580,000 from $20,303,000 for the three months ended March 31, 2007 (“Fiscal 2007”). The decrease was primarily due to decreases in demand for Lannett’s products used for the treatment of epilepsy, and for antibiotic drugs, partially offset by increases in the demand for products used for the treatment of thyroid deficiency. Competitor changes in Fiscal 2007 led to an increase in sales in Fiscal 2007 for antibiotic drugs. The Company looks to continue increasing the number of products available for sale to our customers. FDA approvals are needed to continue this growth. A slowdown in FDA approvals resulted in fewer sales of new products to replace declines in existing product sales. The 18% sales decline of $3,723,000 is primarily due to the following significant causes:

Medical indication	Sales volume change %		Sales price change %
Antibiotics	-30	%	-37	%
Thyroid	5	%	6	%
Epilepsy	- 38	%	- 37	%

Antibiotic drugs experienced a large decrease in sales price and volume which is largely due to an increase in competition. Thyroid drugs changes were due to acquiring new customers at better prices. Epilepsy drugs were affected by both price and volume declines. All other products changes have been minor, and reflect changes associated with normal business operations. These changes may not be indicative of the full year sales change.

The decline in product sales can be attributed primarily to three products. Sales of drugs for the treatment of epilepsy decreased by approximately $1,255,000 in the third quarter of Fiscal 2008 compared to the third quarter of Fiscal 2007 because the Company is no longer the primary manufacturer of the 50mg sized tablet. Sales of generic antibiotics declined by approximately $3,017,000. This decline can be attributed primarily to lower

product sales prices as a result of increased competition. In early Fiscal 2007, several other manufacturers of the largest selling product had technical problems in their manufacturing process, resulting in less competition for our tablet. Sales of drugs used in the treatment of thyroid deficiency increased to offset part of the declines from the other two products. This increase was due to an increase in sales to non-wholesale customers, primarily one large retail chain customer, partially offset by a decrease in sales to one major wholesaler/distributor.

The Company sells its products to customers in various categories. The table below identifies the Company’s approximate net sales to each category for the three months ended March 31, 2008 and 2007:

	Three Months Ended March 31,
Customer Category	2008		2007
Wholesaler/ Distributor	$	7,152,000	$	12,100,000
Retail Chain	8,465,000		6,981,000
Mail-Order Pharmacy	892,000		1,129,000
Private Label	71,000		93,000

Total	$	16,580,000	$	20,303,000

The decrease in sales to wholesaler/distributor customers is due primarily to a decrease in sales of a number of product lines to one of the major wholesalers/distributors. Sales of thyroid deficiency drugs to one of our retail customers increased substantially during the period.

Cost of sales for the third quarter decreased 16% to $12,682,000 in Fiscal 2008 from $15,090,000 in Fiscal 2007. The decrease is due to the 18% decrease in sales. Gross profit margins for the third quarter of Fiscal 2008 and Fiscal 2007 were 24% and 26%, respectively. Gross profit percentage decreased due to price erosion of margins in some products, primarily antibiotics and epilepsy medications, partially offset by decreased product royalty costs, better sales of thyroid medication and the introduction of a new drug during the past year. While the Company is continuously striving to keep product costs low, there can be no guarantee that profit margins will not fluctuate in future periods. Pricing pressure from competitors and costs of producing or purchasing new drugs may also fluctuate in the future. Changes in the future sales product mix may also occur. These changes may affect the gross profit percentage in future periods. In the current period, the Company has changed the presentation of amortization of intangibles and product royalty expenses, in an effort to comply with the SEC’s Staff Accounting Bulletin Topic 11-B (SAB 11-B). SAB 11-B gives guidance on presentation of depreciation and depletion. Specifically, the SEC states “To avoid placing undue emphasis on “cash flow,” depreciation, depletion and amortization should not be positioned in the income statement in a manner which results in reporting a figure for income before depreciation.” Management has presented amortization and product royalties prior to gross profit in order to align the financial reporting with this SEC guidance. Prior periods have been restated to be consistent with the current presentation.

Amortization expense for the intangible asset for each of the three months ended March 31, 2008 and 2007 was approximately $446,000. The amortization expense relates to the March 23, 2004 exclusive marketing and distribution rights agreement with JSP. For the remaining six years of the contract, the Company will incur annual amortization expense of approximately $1,785,000.

Research and development (“R&D”) expenses in the third quarter decreased 33% to $1,517,000 for Fiscal 2008 from $2,270,000 for Fiscal 2007. The decrease is primarily due to a decrease in production of drugs in development and preparation for submission to the FDA. The Company expenses all production costs as R&D until the drug is approved by the FDA. R&D expenses may fluctuate from period to period, based on R&D plans for submission to the FDA.

Selling, general and administrative expenses in the third quarter increased 61% to $4,222,000 in Fiscal 2008 from $2,616,000 in Fiscal 2007. The increase is primarily due to $951,000 of general and administrative expenses incurred in the third quarter by Cody which was acquired in the fourth quarter of Fiscal 2007. Other expenses related to personnel and outside services rendered in legal, accounting and professional services increased nearly $600,000 over the same period in Fiscal 2007. While the Company is focused on controlling costs, increases in personnel costs may have an ongoing and longer lasting impact on the administrative cost structure. Other costs are being incurred to facilitate improvements in the Company’s infrastructure. These costs are expected to be temporary investments in the future of the Company and may not continue at the same level. However, as the Company continues to invest in technology, the Company may need to invest additional funds in technology or professional services.

The Company’s interest expense in the third quarter decreased slightly to $75,000 in Fiscal 2008 from $76,000 in Fiscal 2007. Interest income in the third quarter decreased to $45,000 in Fiscal 2008 from $99,000 in Fiscal 2007 due to a lower level of invested funds.

The Company had an income tax benefit in the third quarter of 2008 of $615,000 compared to $819,000 in Fiscal 2007 due to a net loss before income taxes in both 2007 and 2008. The tax rate for the three months ended March 31, 2008 is 33%, compared to 11% for the three months ended March 31, 2007. The difference is due to permanent differences between tax and book income and loss during each period, primarily related to the write-off of the Cody Labs receivable in the quarter ended March 31, 2007. Additional benefits were recorded during 2008 resulting from research and development tax credits claimed for the first time during 2008.

The Company reported a net loss of approximately $1,256,000 in the third quarter of Fiscal 2008, or ($0.05) basic and diluted loss per share, as compared to net loss of approximately $6,607,000 in the third quarter Fiscal 2007, or ($0.27) basic and diluted loss per share.

Results of Operations - Nine months ended March 31, 2008 compared with nine months ended March 31, 2007

Net sales for the nine months ended March 31, 2008 (“Fiscal 2008”) decreased 21% to $51,654,000 from $65,187,000 for the nine months ended March 31, 2007 (“Fiscal 2007”). The decrease was primarily due to price changes as a result of a decrease in demand for Lannett’s drugs used in the treatment of epilepsy and antibiotic drugs. Competitor changes in Fiscal 2007 led to an increase in sales in Fiscal 2007. In addition, fewer drug approvals from the FDA over the past 12 months have hindered the Company’s growth. The Company looks to continue increasing the number of products available for sale to our customers. FDA approvals are needed to continue this growth. Conversely, a slowdown in FDA approvals resulted in fewer sales of new products to replace declines in existing product sales. The following table highlights the reasons for the decrease, and the percentage each area had on the overall decrease of $13,533,000:

Medical indication	Sales volume change %		Sales price change %
Antibiotics	-12	%	-52	%
Epilepsy	-35	%	- 34	%
Heart Failure	-19	%	10	%
Thyroid	- 2	%	8	%

Consistent with the current quarter changes, epilepsy drugs were affected by both price and volume declines. Antibiotic drugs experienced a decrease in both sales volume and price. These declines were primarily due to the increased competition. Thyroid drug changes were a result of slightly lower unit sales sold at increased prices.

All other products changes have been minor, and reflect changes associated with normal business operations. These changes may not be indicative of the full year sales change.

The decline in product sales can be attributed primarily to two products. Sales of drugs for the treatment of epilepsy decreased by approximately $3,757,000 in the nine months ended March 31, 2008 compared to the nine months ended March 31, 2007 because the Company is no longer the primary manufacturer of the 50mg sized tablet. Sales of generic antibiotics declined $10,134,000. This decline can be attributed primarily to lower product sales prices as a result of increased competition. In early Fiscal 2007, several other manufacturers of the largest selling product had technical problems in their manufacturing process, resulting in fewer competitors selling this drug.

The Company sells its products to customers in various categories. The table below identifies the Company’s approximate net sales to each category:

	Nine Months Ended March 31,
Customer Category	2008		2007
Wholesaler/ Distributor	$	22,775,000	$	40,692,000
Retail Chain	25,478,000		20,167,000
Mail-Order Pharmacy	3,074,000		4,138,000
Private Label	327,000		190,000

Total	$	51,654,000	$	65,187,000

Cost of sales for the first nine months decreased 20% to $38,224,000 in Fiscal 2008 from $47,855,000 in Fiscal 2007. The decrease is due to the 21% decrease in sales. Gross profit margins for the first nine months of Fiscal 2008 and Fiscal 2007 were 26% and 27%, respectively. Gross profit percentage decreased due to price erosion of margins in some products, primarily antibiotics and epilepsy medications, partially offset by decreased product royalty costs, better sales of thyroid medication and the introduction of a new drug during the past year. While the Company is continuously striving to keep product costs low, there can be no guarantee that profit margins will not fluctuate in future periods. Pricing pressure from competitors and costs of producing or purchasing new drugs may also fluctuate in the future. Changes in the future sales product mix may also occur. These changes may affect the gross profit percentage in future periods. In the current period, the Company has changed the presentation of amortization of intangibles and product royalty expenses, in an effort to comply with the SEC’s Staff Accounting Bulletin Topic 11-B (SAB 11-B). SAB 11-B gives guidance on presentation of depreciation and depletion. Specifically, the SEC states “To avoid placing undue emphasis on “cash flow,” depreciation, depletion and amortization should not be positioned in the income statement in a manner which results in reporting a figure for income before depreciation.” Management has presented amortization and product royalties prior to gross profit in order to align the financial reporting with this SEC guidance. Prior periods have been restated to be consistent with the current presentation.

Amortization expense for the intangible asset for each of the nine months ended March 31, 2008 and 2007 was approximately $1,339,000. The amortization expense relates to the March 23, 2004 exclusive marketing and distribution rights agreement with JSP.

Research and development (“R&D”) expenses in the first nine months decreased 34% to $3,715,000 for Fiscal 2008 from $5,586,000 for Fiscal 2007. The decrease is primarily due to a decrease in production of drugs in development and preparation for submission to the FDA. The Company expenses all production costs as R&D until the drug is approved by the FDA. R&D expenses may fluctuate from period to period, based on R&D plans for submission to the FDA.

Selling, general and administrative expenses in the first nine months increased 61% to $12,457,000 in Fiscal 2008 from $7,740,000 in Fiscal 2007. The increase is primarily due to $2,778,000 of general and administrative expenses incurred by Cody which was acquired in the fourth quarter of Fiscal 2007. The remaining increase in expense is due to $272,000 of bad debt expense, increased legal expense of $357,000, and other professional fees increases. While the Company is focused on controlling costs, increases in personnel costs may have an ongoing and longer lasting impact on the administrative cost structure. Other costs are being incurred to facilitate improvements in the Company’s infrastructure. These costs are expected to be temporary investments in the future of the Company and may not continue at the same level. However, as the Company continues to invest in technology, the Company may need to invest additional funds in technology or professional services.

The Company’s interest expense in the first nine months increased to $291,000 in Fiscal 2008 from $208,000 in Fiscal 2007 primarily as a result of increased debt as a result of the Cody acquisition. Interest income in the first nine months decreased to $171,000 in Fiscal 2008 from $310,000 in Fiscal 2007.

The Company had an income tax benefit in the first nine months of 2008 of $821,000, an effective rate of 29%, compared to income tax expense of $686,000, an effective rate of (19%), in Fiscal 2007. The Company incurred a net loss before income taxes in 2008. In 2007, net loss before taxes was offset by permanent differences primarily related to the write-off of the Cody Labs receivable in the third quarter of Fiscal 2007.

The Company reported net loss of $2,041,000 in the first nine months of Fiscal 2008, or ($0.08) basic and diluted loss per share, as compared to a net loss of $4,354,000 in the first nine months Fiscal 2007, or ($0.18) basic and diluted loss per share.

Liquidity and Capital Resources

The Company has historically financed its operations by cash flow from operations. At March 31, 2008, working capital was $22,672,000, as compared to $22,035,000 at June 30, 2007, an increase of $637,000. Net cash provided by operating activities of $2,971,000 in the first nine months of Fiscal 2008 is due to a net loss of $2,041,000, adjustments for the effects of non-cash items of $4,005,000 and a net use of cash from changes in operating assets and liabilities of $1,007,000. Significant changes in operating assets and liabilities are comprised of:

· A decrease in accrued expenses of $3,754,000 due to a high level of accrual for materials received at the end of fiscal 2007 primarily related to distributed products.

· A decrease in trade accounts receivable of $989,000 is due to an increase in processing of usual and customary chargeback and rebate credits claimed by customers.

· An increase in accounts payable of $1,773,000 due to the timing of payments at the end of the month combined with increased spending on products for resale, primarily Levothyroxine Sodium tablets.

· A decrease in inventory of $2,500,000 due to a decrease in the level of inventory of distributed products during the period.

The net cash used in investing activities of $1,133,000 for the nine months ended March 31, 2008 was due to the purchases of fixed assets during the quarter, offset by the sale of some investment securities.

The following table summarizes the remaining repayments of debt, including sinking fund requirements as of March 31, 2008 for the subsequent twelve month periods:

Twelve	Amounts Payable
Month Periods	to Institutions
2008	$	703,570
2009	562,721
2010	4,925,541
2011	291,471
2012	280,291
Thereafter	2,473,157

	$	9,236,751

The following table represents annual debt, lease and contractual purchase obligations as of March 31, 2008:

	Total		Less than 1 year		1-3 years		3-5 years		more than 5 years

Long-Term Debt	$	9,236,751	$	703,570	$	5,488,262	$	571,762	$	2,473,157
Operating Leases	1,528,013		470,628		868,523		188,862		—
Purchase Obligations	135,000,000		19,000,000		41,000,000		45,000,000		30,000,000
Interest on Obligations	2,104,198		293,109		607,447		364,967		838,675
Total	$	147,868,962	$	20,467,307	$	47,964,232	$	46,125,591	$	33,311,832

The terms of the line of credit, the loan agreement, the related letter of credit and the 2003 Loan Financing require that the Company meet certain financial covenants and reporting standards, including the attainment of standard financial liquidity and net worth ratios.

In July 2004, the Company received $500,000 of grant funding from the Commonwealth of Pennsylvania, acting through the Department of Community and Economic Development. The grant funding program requires the Company to use the funds for machinery and equipment located at their Pennsylvania locations, hire an additional 100 full-time employees by June 30, 2007, operate its Pennsylvania locations a minimum of five years and meet certain matching investment requirements. The Company complied with two of the three requirements above and the requirement to operate its Pennsylvania locations is still ongoing, however, the Company failed to comply with hiring an additional 100 full-time employees. The Company is currently providing information to the Department of Community and Economic Development to grant an extension or waive the obligation of hiring an additional 100 full-time employees. The Company will be liable to repay the full amount of the grant funding ($500,000) if an extension or waiver is not received. The Company records the unearned grant funds as a liability until the Company complies with all of the requirements of the grant funding program. On a quarterly basis, the Company monitors its progress in fulfilling the requirements of the grant funding program and will determine the status of the liability. As of March 31, 2008, the grant funding is recognized as a short term liability under the caption of Unearned Grant Funds, since the Company has not yet met the requirement to add 100 full-time employees.

Except as set forth in this report, the Company is not aware of any trends, events or uncertainties that have or are reasonably likely to have a material adverse impact on the Company’s short-term or long-term liquidity or financial condition.

Prospects for the Future

The Company has several generic products under development. These products are all orally-administered, topical and parenteral products designed to be generic equivalents to brand named innovator drugs. The Company’s developmental drug products are intended to treat a diverse range of indications. As the oldest generic drug manufacturer in the country, formed in 1942, Lannett currently owns several ANDAs for products which it does not manufacture and market. These ANDAs are simply dormant on the Company’s records. Occasionally, the Company reviews such ANDAs to determine if the market potential for any of these older drugs has recently changed, so as to make it attractive for Lannett to reconsider manufacturing and selling it. If the Company makes the determination to introduce one of these products into the consumer marketplace, it must review the ANDA and related documentation to ensure that the approved product specifications, formulation and other factors meet current FDA requirements for the marketing of that drug. The Company would then redevelop the product and submit it to the FDA for supplemental approval. The FDA’s approval process for ANDA supplements is similar to that of a new ANDA. Generally, in these situations, the Company must file a supplement to the FDA for the applicable ANDA, informing the FDA of any significant changes in the manufacturing process, the formulation, or the raw material supplier of the previously-approved ANDA.

A majority of the products in development represent either previously approved ANDAs that the Company is planning to reintroduce (ANDA supplements), or new formulations (new ANDAs). The products under development are at various stages in the development cycle—formulation, scale-up, and/or clinical testing. Depending on the complexity of the active ingredient’s chemical characteristics, the cost of the raw material, the FDA-mandated requirement of bioequivalence studies, the cost of such studies and other developmental factors, the cost to develop a new generic product varies. It can range from $100,000 to $1 million. Some of Lannett’s developmental products will require bioequivalence studies, while others will not—depending on the FDA’s Orange Book classification. Since the Company has no control over the FDA review process, management is unable to anticipate whether or when it will be able to begin producing and shipping additional products.

In addition to the efforts of its internal product development group, Lannett has contracted with several outside firms for the formulation and development of several new generic drug products. These outsourced R&D products are at various stages in the development cycle — formulation, analytical method development and testing and manufacturing scale-up. These products are orally-administered solid dosage, injectable, as well as topical products intended to treat a diverse range of medical indications. It is the Company’s intention to ultimately transfer the formulation technology and manufacturing process for all of these R&D products to the Company’s own commercial manufacturing sites. The Company initiated these outsourced R&D efforts to complement the progress of its own internal R&D efforts.

Lannett also manufactures and sells products which are equivalent to innovator drugs which are grand-fathered, under FDA rules, prior to the passage of the Hatch-Waxman Act of 1984. The FDA allows generic manufacturers to produce and sell generic versions of such grand-fathered products by simply performing and internally documenting the product’s stability over a period of time. Under this scenario, a generic company can forego the time required for FDA ANDA approval.

The Company signed supply and development agreements with Olive Healthcare, of India; Orion Pharma, of Finland; Azad Pharma AG, of Switzerland, Unichem Inc. of India, Wintac Limited of India, Pharmaseed of Israel and Banner Pharmacaps of the United States, and is in negotiations with companies in Israel and China for similar new product initiatives, in which Lannett will market and distribute products manufactured by Lannett or by third parties. Lannett intends to use its strong customer relationships to build its market share for such products, and increase future revenues and income.

The majority of the Company’s R&D projects are being developed in-house under Lannett’s direct supervision and with Company personnel. Hence, the Company does not believe that its outside contracts for product development and manufacturing supply are material in nature, nor is the Company substantially dependent on the services rendered by such outside firms. Since the Company has no control over the FDA review process, management is unable to anticipate whether or when it will be able to begin producing and shipping such additional products.

Lannett may increase its focus on certain specialty markets in the generic pharmaceutical industry. Such a focus is intended to provide Lannett customers with increased product alternatives in categories with relatively few market participants. While there is no guarantee that Lannett has the market expertise or financial resources necessary to succeed in such a market specialty, management is confident that such future focus will be well received by Lannett customers and increase shareholder value in the long run.

The Company plans to enhance relationships with strategic business partners, including providers of product development research, raw materials, active pharmaceutical ingredients as well as finished goods. Management believes that mutually beneficial strategic relationships in such areas, including potential financing arrangements, partnerships, joint ventures or acquisitions, could allow for potential competitive advantages in the generic pharmaceutical market.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company has debt instruments with variable interest rates. The Equipment Loan, amounting to $482,000 at March 31, 2008, bears interest at a variable rate equal to the LIBOR rate plus 150 basis points. In addition, the Company has a $3 million line of credit from Wachovia Bank, N.A. that bears interest at the prime interest rate less 0.25% (5.25% at March 31, 2008). The Company currently has $2,083,000 available under this line of credit. The Company has entered into a letter of credit for $917,000 with a supplier which has reduced the amount available under the line of credit. The line of credit was renewed and extended to November 30, 2009. The line of credit is collateralized by substantially all of the Company’s assets. The agreement contains covenants with respect to working capital, net worth and certain ratios, as well as other covenants.

The Company invests in U.S. treasury notes, and government asset-backed securities, all of which are exposed to interest rate fluctuations. The interest earned on these investments may vary based on fluctuations in the interest rate.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this Form 10-Q, management performed, with the participation of our Chief Executive Officer and Chief Financial Officer, an evaluation of the effectiveness of our disclosure controls and procedures as defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosures. As part of this evaluation, our management considered the material weaknesses described in our 2007 Form 10-K filed with the SEC on October 9, 2007.

We have engaged in, and continue to engage in, substantial efforts to address the material weakness in our internal control over financial reporting and the ineffectiveness of our disclosure controls and procedures as disclosed in our 2007 Form 10-K.

Because of the material weaknesses identified in our 2007 Form 10-K, we performed additional procedures, where necessary, so that our Consolidated Financial Statements for the period covered by this Form 10-Q are presented in accordance with GAAP. These procedures included, among other things, validating data to independent source documentation; reviewing our existing contracts to determine proper financial reporting; and performing additional closing procedures, including detailed reviews of journal entries, re-performance of account reconciliations and analyses of balance sheet accounts.

Based upon the evaluation and based upon the remediation measures taken to address the material weaknesses identified in our 2007 Form 10-K, the Chief Executive Officer and Chief Financial Officer concluded that the Company’s disclosure controls and procedures were effective as of the end of the period covered by this report.

Change in Internal Control Over Financial Reporting

There has been no change in the Company’s internal control over financial reporting during the three months ended March 31, 2008 that has materially affected, or reasonably likely to materially affect, our internal control over financial reporting, other than additional controls that have been implemented that have remediated the material weaknesses identified in the Company’s Form 10-K as of June 30, 2007.

Since they were identified, the Company has implemented controls to remediate its material weakness associated with the misstatement of costs of goods sold through the following actions:

· Including work in process (WIP) inventory in cycle counting and quarterly count procedures.

· Reconciliation of systems transactions to be performed and reviewed on a monthly basis to ensure that WIP value in inventory systems agrees to WIP value in general ledger accounts.

· Revision of monthly closing checklist to include each trial balance account, and identify a specific person responsible for reconciling and reviewing each account as appropriate.

· Analysis of detailed WIP inventory and corroborating review of such analysis, to ensure the balance is reasonable in comparison to actual production activities.

· Engage SAP consulting experts to review processes that are used to close WIP batches.

The Company has implemented controls to remediate its material weakness associated with the impairment of notes receivable as of March 31, 2007 through the following actions:

· Formalize Company policy to require either CEO or CFO signature on all material company contracts.

· Formalize Company policy to require legal review of all material Lannett contracts prior to execution.

· Formalize Company policy to require all material Lannett contracts are provided to Lannett’s Corporate Controller and CFO in a timely manner to allow for appropriate accounting review and analysis.

· Require a quarterly report from Lannett’s outside attorney identifying all Lannett contracts reviewed during that quarter.

· Lannett’s Disclosure Committee will review the outside attorney provided quarterly report to determine materiality and appropriate disclosure.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Regulatory Proceedings

The Company is engaged in an industry which is subject to considerable government regulation relating to the development, manufacturing and marketing of pharmaceutical products. Accordingly, incidental to its business, the Company periodically responds to inquiries or engages in administrative and judicial proceedings involving regulatory authorities, particularly the FDA and the Drug Enforcement Agency.

ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The annual meeting of shareholders was held on January 24, 2008. The following proposals were adopted by the margins indicated:

1. To elect seven (7) members of the Board of Directors to serve until the next Annual Meeting of Stockholders and until their respective successors have been duly elected and qualified.

Director	Votes for	Votes against	Votes withheld
William Farber	22,477,249	0	859,435
Ronald West	23,164,815	0	171,869
Arthur Bedrosian	23,248,335	0	88,349
Jeffrey Farber	23,255,835	0	80,849
Kenneth Sinclair	22,912,875	0	423,809
Albert Wertheimer	23,207,575	0	129,109
Myron Winkelman	23,097,915	0	238,769

2. To approve the appointment of Grant Thornton LLP as independent auditors.

For:		23,276,343
Against:		52,982
Abstain:		7,359

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

(a) A list of the exhibits required by Item 601 of Regulation S-K to be filed as a part of this Form 10-Q is shown on the Exhibit Index filed herewith.

SIGNATURE

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		LANNETT COMPANY, INC.

Dated: May 15, 2008	By:	/s/ Brian Kearns
		Brian Kearns
		Vice President of Finance, Treasurer and
		Chief Financial Officer

Dated: May 15, 2008	By:	/s/ Arthur P. Bedrosian
		Arthur P. Bedrosian
		President and Chief Executive Officer

Exhibit Index

31.1	Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Herewith

31.2	Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002	Filed Herewith

32	Certifications of Chief Executive Officer and Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	Filed Herewith

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED STATEMENTS OF CASH FLOWS

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS - UNAUDITED

ITEM 2.

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS.